


Comprehensive Dual- and Triple-Feature Intersectional Single-Vector Delivery of Diverse Functional Payloads to Cells of Behaving Mammals

Graphical Abstract



Authors

Lief E. Fenno, Charu Ramakrishnan,
Yoon Seok Kim, ...,
Nandini Pichamoorthy,
Alice S.O. Hong, Karl Deisseroth

Correspondence

deissero@stanford.edu

In Brief

Fenno et al. enable versatile functional access to cell types defined by the presence of multiple (2 or 3) features, creating diverse expression-control logic contained in single viruses. This result is a comprehensive toolset enabling multiple-feature-dependent optogenetic inhibition and excitation and structure- or activity-based fluorescence imaging with diverse new indicators.

Highlights

- Multiple recombinase-dependent expression of 15 new molecular payloads in single AAVs
- Intersectional Ca^{2+} imaging, cell labeling, and optogenetic inhibition or excitation
- Creation and *in vivo* validation of triple-feature-dependent viruses (Triplesect)
- Design of a widely adaptable *in vivo* quantitative expression tracking system



NeuroResource

Comprehensive Dual- and Triple-Feature Intersectional Single-Vector Delivery of Diverse Functional Payloads to Cells of Behaving Mammals

Lief E. Fenno,^{1,2,4} Charu Ramakrishnan,^{2,4} Yoon Seok Kim,^{2,4} Kathryn E. Evans,² Maisie Lo,² Sam Vesuna,² Masatoshi Inoue,² Kathy Y.M. Cheung,² Elle Yuen,² Nandini Pichamoorthy,² Alice S.O. Hong,² and Karl Deisseroth^{1,2,3,5,*}

¹Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA 94305, USA

²Department of Bioengineering, Stanford University, Stanford, CA 94305, USA

³Howard Hughes Medical Institute, Stanford University, Stanford, CA 94305, USA

⁴These authors contributed equally

⁵Lead Contact

*Correspondence: deissero@stanford.edu

<https://doi.org/10.1016/j.neuron.2020.06.003>

SUMMARY

The resolution and dimensionality with which biologists can characterize cell types have expanded dramatically in recent years, and intersectional consideration of such features (e.g., multiple gene expression and anatomical parameters) is increasingly understood to be essential. At the same time, genetically targeted technology for writing in and reading out activity patterns for cells in living organisms has enabled causal investigation in physiology and behavior; however, cell-type-specific delivery of these tools (including microbial opsins for optogenetics and genetically encoded Ca^{2+} indicators) has thus far fallen short of versatile targeting to cells jointly defined by many individually selected features. Here, we develop a comprehensive intersectional targeting toolbox including 39 novel vectors for joint-feature-targeted delivery of 13 molecular payloads (including opsins, indicators, and fluorophores), systematic approaches for development and optimization of new intersectional tools, hardware for *in vivo* monitoring of expression dynamics, and the first versatile single-virus tools (Triplesect) that enable targeting of triply defined cell types.

INTRODUCTION

Cellular-resolution investigation of the biology of behaving animals has leveraged powerful, genetically encoded molecular tools that utilize visible light for exchange of information with targeted cells, including optogenetic tools to control cellular events and fluorescent indicators to report cellular signaling and anatomy. However, application of these approaches depends on the ability to selectively express the genetically encoded tools in well-defined cellular subpopulations—with limitations that have become increasingly apparent with the rapid progression of detailed single-cell transcriptomes and connectomes revealing that cell-type definition with only single features is inadequate.

A technique termed INTRSECT (intronic recombinase sites enabling combinatorial targeting) partially addressed this challenge (Fenno et al., 2014), advancing beyond earlier single-feature methods for cell-type targeting (which, in the case of viral tools, was based on enhancer- or anatomy-guided expression of a single recombinase [e.g., Cre] employed in combination with a Cre-dependent virus) (reviewed in Fenno et al., 2011; Yizhar et al., 2011). In contrast, INTRSECT allowed adeno-associated

virus (AAV)-borne molecular payloads to be expressed in cells based on a doubly specified combination of genetically and/or anatomically defined parameters by placing two orthogonal recombinase (Cre and Flp) recognition sequences in synthetic introns (Fenno et al., 2017). Although only enabled for yellow fluorescent protein (EYFP) and the excitatory channelrhodopsin fusion protein ChR2-EYFP, the initial proof-of-concept two-feature INTRSECT has been successfully applied in diverse experimental settings, including for mapping projection patterns of certain neuronal subtypes (Chuhma et al., 2018; Poulin et al., 2018) and for probing the contribution of doubly specified cell populations to diverse motivated behaviors (Gao et al., 2019; Lazaridis et al., 2019; Marcinkiewicz et al., 2016; Tovote et al., 2016). However, the ensuing 6 years have witnessed an explosion in the richness of molecular cell typology, creating a fundamental unmet need for a comprehensive toolset beyond ChR2-EYFP able to investigate the necessity and sufficiency as well as natural activity of targeted cell populations in multiply defined neurons, including dual-feature and triple-feature targeting.

Here we report our development of this toolset, driven by an approach spanning four independent domains of intersectional expression engineering: (1) design of a pipeline for developing

multiple-recombinase-dependent constructs to expand the repertoire of two-feature targeting to a wide array of commonly used molecular tools, bringing the total number of validated intersectional tools from 6 to 45; (2) refinement of the Flp recombinase-dependent components of the viral backbone to significantly enhance Flp-mediated recombination, widening the range of intersectional experimental designs available; (3) quantifying recombinase- and non-recombinase-dependent expression kinetics with a novel device for chronic *in vivo* expression monitoring; and (4) the first triple-intersectional viral technology, validating the resulting tools *in vitro* and *in vivo*. These resources allow detailed and rigorous investigation of the natural and causal roles of cells defined by the intersection of many genetically and/or anatomically specified properties.

RESULTS

Development of the Intersectional Pipeline

INTRSECT combines synthetic introns and dependency on two recombinases (Cre and Flp) to restrict EYFP or ChR2-EYFP to cellular populations specified by two features (Figures 1A–1F). For example, two introns could be inserted into a gene with two reading frames (initially, an opsin-fluorophore fusion gene). The starting configuration of the exons and the recombinase recognition sites (e.g., lox and FRT) determined which logical combination of Cre and Flp would enable expression (Figures 1D and 1E), and the synthetic introns that contained these recombinase sites were reliably removed during mRNA splicing, allowing functional protein to be expressed (Figure 1F).

To create next-generation intersectional tools with a broad diversity of molecular payloads, we began by designing a production pipeline (Figures 1G and 1H). We tested this pipeline by creating novel intersectional viruses for a broad array of commonly used optical tools, implementing new classes of payload as well as incorporating vastly more potent capabilities that have emerged in recent years: fluorescent proteins (mTagBFP, mCherry, and oScarlet; Figure S1; oScarlet and sRGECO are variants of mScarlet and jRGECO1a that we engineered to reduce aggregation, as described in Figures S1A–S1C and S2A–S2E), Ca^{2+} indicators (GCaMP6f, GCaMP6m, and sRGECO; Figure S2), excitatory opsins [ChRmine 3.3-p2a-oScarlet; ChR2(H134R)-mCherry, bReaChES-EYFP, and ChR2(E123T/T159C)-EYFP; Figure S3], and inhibitory opsins (iC++-EYFP; NpHR 3.3-p2a-EYFP, and Arch 3.3-p2a-EYFP; Figure S4). The new pipeline (Figure 1G) was validated through the generalized success of its informatics-based intron placement in generating properly spliced products and by the early identification of occasional two-intron constructs with spurious splice products (allowing modification prior to further characterization *in vitro* or *in vivo*; Figure 2).

When necessary, improving splice fidelity required individualized strategies based on the sequence of the mis-spliced products (Figure 2A); for example, we observed a preferred cryptic splice site in the second exon of bReaChES-EYFP as well as direct splicing of exon 1 to exon 3 (Figure 2B). In this case, simply moving the first intron to a 3' secondary candidate splice site was sufficient to eliminate the cryptic site and exon skipping (Figures 2C and 2D). Separately, mis-splicing at a cryptic site was found

with NpHR 3.3-p2a-EYFP (Figure 2E); in this case, the sequence of NpHR did not offer an additional splice site option, and we were unable to use codon degeneracy to disrupt the cryptic splice site. We instead leveraged the structure of NpHR (Kouyama et al., 2010) to consider that the distance ($>8 \text{ \AA}$) of the residue encoded by the cryptic splice site from the retinal binding pocket would most likely enable engineering of a site that would be non-destructive to protein function (Figure 2F, left); indeed, the introduced mutation W179F did not negatively influence opsin function (Figure 2F, right; $p = 0.9754$, unpaired t test) and successfully resolved mis-splicing (Figure 2G). We anticipate that our algorithmic approach to addressing mis-splicing will be a helpful addition to the standard operating procedure and design manual for INTRSECT implementation (Figure 2H).

Aside from such rare cryptic splice sites, direct exon 1-to-exon 3 splicing was a frequently observed minor splice variant in two-intron (three-exon) constructs. We attenuated this phenomenon with a panel of approaches, including modifying the splice acceptor polypyrimidine tract C/T content, increasing the intron sequence length, and increasing the distance between the introns. None of these approaches completely eliminated exon 1-to-exon 3 direct splicing (data not shown); in fact, even original wild-type (WT) cDNA exhibited the same splice product and sequence in some cases (including in NpHR 3.3(W179F)-p2a-EYFP [Figure S4A] and ChR2(H134R)-mCherry [Figure S3G]), indicative of intrinsic splicing without synthetic introns. These alternatively spliced variants were minor products that did not adversely affect functional expression relative to the WT.

Flow cytometry in HEK293 cells revealed operation as expected for all of the novel Cre AND Flp (Con/Fon) vectors (schematized in Figures 1B and 1E): no expression in the absence of recombinases, an expression level comparable with the WT when paired with activating recombinases, and no off-target expression. The Flp AND NOT Cre (Coff/Fon) constructs exhibited a range of expression associated with tool class: fluorophores and genetically encoded calcium indicators (GECIs) expressed at moderately reduced levels relative to the WT (Figures S1E, S1H, S1K, S2G, S2J, and S2M), whereas excitatory (Figures S3B, S3E, S3H, and S3K) and inhibitory (Figures S4B, S4E, and S4H) opsin expression levels were comparable with those of the WT. Inactivation of Coff/Fon constructs by co-transfection with Cre as well as Flp was effective at diminishing expression to levels similar to negative control levels. For the opposite configuration (Con/Foff, Cre AND NOT Flp), co-transfection with Flp as well as Cre diminished expression in all cases; in some constructs, expression was abolished (i.e., to levels indistinguishable from those of negative controls), whereas in others, expression was decreased by more than an order of magnitude but still detectable 5 days post-transfection. These constructs thus revealed the potential for transient off-target expression in cells co-expressing Cre and Flp, which could occur (for example) if Cre acts before Flp in Con/Foff constructs because of the known higher efficacy of Cre relative to Flp (Ringrose et al., 1998); we address this (Figures S5 and S6) with optimized Flp recombinase-dependent construct design.

Next, regarding function of the resulting correctly assembled constructs in the pipeline, fluorophores were tested by




Figure 1. INTRSECT Strategy and Engineering Pipeline

(A and D) INTRSECT molecular designs for a single open reading frame (ORF; A) and double ORF (D) in three Boolean configurations (Cre AND Flp, Cre AND NOT Flp, Flp AND NOT Cre). Reagents for each configuration are listed.

(B and E) Activity of Cre and Flp to move the single ORF (B) and double ORF (E) INTRSECT starting configurations (top) to the active (dotted box, center) and inactivated (bottom) states.

(C and F) From top to bottom: how the initial DNA configurations for single-ORF (C) and double-ORF (F) constructs transition to the active state after recombinease-dependent rearrangement, mRNA processing that removes introns containing recombinease recognition sites, and translation without addition of an extraneous sequence (crystal structure in C: GCaMP6m, PDB: 3WLD [Ding et al., 2014]; F: iC++ PDB: 6CSN [Kato et al., 2018]).

(G) Standardized engineering pipeline for production of novel INTRSECT constructs consisting of (left to right) design of intron placement and cloning, RT-PCR to ensure proper splicing, flow cytometry to assay proper expression, and functional testing (in cultured neurons or HEK cells) to compare with the parental construct.

(H) Electrophysiology in cultured neurons expressing WT, Con/Fon, Con/Foff, or Coff/Fon variants of ChRmine 3.3-p2a-oScarlet (left) or iC++-EYFP (right) with recombinases.

See also Figures S1–S4.

expression in cultured cells in addition to flow cytometry analysis (Figures S1F, S1I, and S1L). GECIs were transfected into neuronal primary cultures and functionally assayed by electrical field stimulation with single-cell resolution fluorescence [Ca^{2+}]_i imaging. All GECI constructs (sRGECO, GCaMP6f, and GCaMP6m) generated reliable signals. Basal expression from

these intersectional constructs was significantly decreased relative to the parental tool in some cases (Figures S2H and S2K; all versus WT; sRGECO Con/Fon $p = 0.0034$, Con/Foff and Coff/Fon $p < 0.0001$; GCaMP6m Coff/Fon $p = 0.0414$, Kruskal-Wallis test with Dunn's test); [Ca^{2+}]_i signals (dF/F; see Methods) were greater in cases of lower basal fluorescence (Figures S2H and




Figure 2. Standardized INTRSECT Design and Implementation

(A) RT-PCR testing and mis-splicing resolution approach for new INTRSECT constructs.

(B and E) Mis-spliced RT-PCR results for INTRSECT bReaChES-EYFP and NpHR3.3-p2a-EYFP. bReaChES-EYFP (B) and NpHR 3.3-p2a-EYFP (E) had major and minor splice variants from cryptic splicing (denoted by #) and exon 1-to-exon 3 direct splicing (denoted by *).

(C and F) The bReaChES-EYFP intron was moved to an alternative splice site (C). NpHR 3.3-p2a-EYFP did not present options for use of a separate splice site or degenerate codons. Guided by the published crystal structure, we disrupted the cryptic splice site (F, arrow) by introducing the mutation W179F (F, center), which did not affect opsin function (F, right; $p = 0.9754$, unpaired t test).

(D and G) These iterations of bReaChES-EYFP (D) and NpHR 3.3-p2a-EYFP (G) generated single spliced products (D) or the correct major product and an exon 1-exon 3 minor splice variant (G).

(H) To catch errors early during scaling and implementation, we described a protocol for making new INTRSECTs (Fenno et al., 2017) and maintain a standard operating procedure (http://www.optogenetics.org/intrsect_sop.pdf).

See also Figures S1–S4.

S2N; sRGECO Con/Fon $p = 0.0161$, Con/Foff and Coff/Fon $p < 0.0001$, GCaMP6f Con/Fon $p = 0.0468$, Coff/Fon $p < 0.0001$, Kruskal-Wallis test with Dunn's test). Whole-cell electrophysiology of opsin variants under photostimulation was generally indistinguishable compared with WT/parental constructs (Figures S3C, S3F, S3I, S3L, S4C, and S4I), with the exception of Arch 3.3-p2a-EYFP, where Con/Fon and Con/Foff exhibited moderately diminished photocurrents in culture ($p < 0.05$ for

both, ANOVA with Dunnett's test). To explore this effect, we produced AAVs of the parental and Arch 3.3-p2a-EYFP constructs and co-injected these with AAVs encoding activating recombinases (Ef1a-Cre, Ef1a-Flp, and Ef1a-Flp-2a-Cre) into the mouse hippocampus for further evaluation by slice electrophysiology. In contrast to photocurrents observed after 1 week of cultured neuron expression, we found that photocurrents with intersectional Arch 3.3-p2a-EYFP tools in slice 4 weeks post-injection

(a more natural application setting than cultured neurons) were indistinguishable from WT Arch 3.3-p2a-EYFP (Figure S4F; Con/Fon $p = 0.3966$, Con/Foff $p = 0.9286$, Coff/Fon $p < 0.0001$, ANOVA with Dunnett's test).

This new molecular engineering pipeline, which identifies sub-optimal function early in the production process (Figure 2A) and enables efficient creation of intersectional constructs *in silico* that function well out of the gate after cloning (Figure 1G), allowed systematic generation and validation of a broad repertoire of intersectional viral tools for precision cell-type investigation in biology and brings the total number to 45; at the same time, this algorithmic approach was crucial for creating the triple-recombinase-dependent virus described below.

Improvement of the FRT Cassette

Although flow cytometry data largely matched functional expression when constructs were paired with correct recombinases, we consistently observed a minor population of cells with residual expression 5 days after co-transfection of Con/Foff constructs with Cre and Flp. We hypothesized that this pattern might result from inefficiency of Flp relative to Cre, characterized to be an order of magnitude less efficient at equimolar concentrations *in vitro* (Ringrose et al., 1998). We therefore sought to reduce this off-target expression by screening Con/Foff variants containing modifications of the Flp-dependent elements for increased sensitivity to Flp-mediated recombination.

The Flp-dependent cassette (Figure S5A, top) utilizes two independent Flp recognition elements in the double-floxed inverted open reading-frame (DIO; Zhang, 2008) configuration for recombinase-dependent inversion of exons (Zhang, 2008; Atasoy et al., 2008; Sohal et al., 2009). The original INTRSECT design utilized the F3 and F5 sequences (Schlake and Bode, 1994), chosen to avoid potential intermolecular recombination between virus and the genome of transgenic Cre-expressing animal lines, some of which may contain a residual FRT sequence. Here we used a rational screening approach that started with a wide range of Con/Foff-EYFP variants (Figure S5A, bottom) and further modified promising ones. Candidates were screened by flow cytometry *in vitro* to evaluate mean EYFP intensity of the residual population as well as the percentage of the parent population these residuals represent (Figure S5B). We found that replacing the F3 site with FRT (FRT/F5) or a modified form containing an additional 14-bp palindromic sequence (14bp-FRT/F5) significantly decreased the residual expression signal as well as the percentage of cells that continued to aberrantly express EYFP 5 days post-transfection, while maintaining high expression in the active configuration (co-transfected with Cre alone; Figure S5C).

We next assayed whether this improvement in function at an equimolar Flp:Cre ratio was maintained across other Flp:Cre ratios by comparing our original Con/Foff-EYFP with these two variants and systematically varying the relative amounts of Cre and Flp. Both candidate plasmids maintained their improved expression pattern across a wide range of recombinase ratios (Figures S5D, top and S5E, top). Consistent with our hypothesis that residual expression is driven by inefficiency of Flp relative to Cre, ratios of Flp:Cre beyond 1:1 reduced residual expression,

whereas ratios greater than 10:1 contributed marginal improvement as expression neared fitted floor values for mean expression and fraction of the population with residual expression (R^2 mean expression original configuration $v1 = 0.8028$, variant $g = 0.7114$, variant $o = 0.6921$; R^2 fraction with residual expression original configuration $v1 = 0.2793$, variant $g = 0.5848$, variant $o = 0.3983$). The magnitude of the improvement was equivalent between these two variants (Figures S5D, bottom and S5E, bottom; all $p > 0.25$, ANOVA with Sidak's test). Last, we evaluated the performance of these two variants *in vivo* in cohorts co-injected with AAV-Con/Foff-EYFP incorporating the functional components of variants $v1$, g , or o and AAV-Cre or AAV-Flp-2a-Cre. *In vivo* performance closely parallel our *in vitro* observations, with variants g and o outperforming variant $v1$ and negligible difference between them (Figure S5F; residual signal relative to $v1$ $p = 0.0009$ variant g , $p = 0.0008$ variant o , ANOVA with Dunnett's test). Because these two variants appeared to be equivalent *in vitro* and *in vivo*, we chose to continue with the FRT/F5-based variant to simplify cloning and decrease payload size.

We integrated this improved Flp cassette into all Con/Foff constructs from the comprehensive new intersectional toolbox and compared the original (F3/F5) and improved (FRT/F5) versions (Figures S5G–S5I) across all tools. As expected, when transfected with Cre alone, we found no significant difference between original and improved versions in the mean signal or fraction of positive cells (Figure S5G; Con/Foff-EYFP versus Con/Foff-(FRT/F5)-EYFP, mean signal $p = 0.46$, fraction of positive cells $p = 0.47$, paired t tests). In contrast, when co-transfected with equimolar amounts of Cre and Flp, the FRT/F5 constructs performed significantly better than their F3/F5 counterparts (Figure S5H; Con/Foff-EYFP versus Con/Foff-(FRT/F5)-EYFP, mean signal $p = 0.0069$, fraction of positive cells $p = 0.010$, paired t tests). To assay whether the observed differences were due to changes specific to Flp activity or to overall construct expression, we additionally analyzed the data by normalizing inactive (Cre and Flp) to paired active (Cre alone) data and found that the consistent improvement seen with FRT/F5 is largely driven by a Flp-dependent reduction in the residual fraction of positive cells (Figure S5I; mean signal $p = 0.080$, fraction of positive cells $p = 0.0010$). To further assess the function of Con/Foff-(FRT/F5)-EYFP *in vivo*, we injected AAV-Con/Foff-(FRT/F5)-EYFP into the mPFC and dorsal hippocampus of $Sst^{tm(Cre)}$ (SST-Cre) animals, either alone or with AAV-Flp (Figures S6A–S6D); 4 weeks after surgery, we observed robust expression of EYFP when injected alone and extinguished expression when co-injected with Flp that was indistinguishable from uninjected WT controls.

We recommend that Con/Foff experimental designs utilize ratios of Flp:Cre that favor Flp, ideally with a 10:1 ratio, which may be achieved through viral delivery or utilizing Flp transgenic lines with high expression. Our characterization of the Flp cassettes, and the function of the intersectional Con/Foff backbone in particular, illustrates the importance of quantifying and addressing potential off-target expression and provides a practical evaluation framework to enable wider adoption of the intersectional expression platform specifically and Flp-dependent constructs more generally.




Figure 3. Chronic Monitoring of Viral Expression: Equivalent INTRASECT and WT Expression Kinetics

(A) Expression monitoring device: a light emitting diode (LED) light source fed into a filter cube and coupled to a visible-wavelength spectrometer for emission detection.

(legend continued on next page)

Modeling Intersectional Virus Kinetics *In Vivo* via a Novel Spectroscopy Device

We next turned our attention to characterizing the *in vivo* dynamics of intersectional viruses to ask whether recombinase dependence would change rate of expression *in vivo* and to provide guidance regarding experimental design incorporating intersectional viruses. Expression-kinetics parameters of non-recombinase-dependent AAV8 have been characterized previously by histology (Klein et al., 2006; Reimsnider et al., 2007), showing that expression velocity peaks at 2–3 weeks, followed by a plateau. To our knowledge, there is no published study that thoroughly quantifies the expression time course of commonly employed and/or new optical tools *in vivo*; this knowledge void could result in heterogeneity among experimental designs employing AAV-delivered molecular tools. Because behavioral experiments are frequently conducted over days to weeks, experimental designs that do not wait for peak viral expression may result in recruitment of changing populations (more or fewer) neurons over time.

To address this data void, we designed (for broad applicability and availability) a robust and inexpensive device for adoption in laboratories across biology (even without infrastructure for microscopy or imaging, requiring only a simple visible-wavelength spectrometer) to track expression dynamics, using off-the-shelf components to assay fluorescence emission from fluorophore expression *in vivo* (Figure 3A). The relationship between the spectrometer's tunable integration time and counted photons was verified to be linear for a fluorescein slide (Figure 3B; $R^2 = 0.9999$) and *in vivo* virally expressed EYFP (Figures 3C and 3D; $R^2 = 0.9999$). To assay expression over weeks, we chose to follow measurements across a wide range of integration times to enable sensitivity to low expression (with longer integration times) while maintaining the ability to quantify high expression (with shorter integration times). The resulting expression score metric (Figures 3E) spanned many orders of magnitude; to pool data across animals, we log-transformed and normalized scores (Figure 3F) to model expression (Figure 3G and 3H).

We applied this approach to the three dual-parameter, intersectional logical configurations to characterize expression ki-

netics and compare them with WT EYFP. We prepared cohorts of animals injected with AAV-EF1a viruses delivering EYFP, Con/Fon-EYFP + Flp-2a-Cre, Con/Foff-(FRT/F5)-EYFP + Cre, or Coff/Fon-EYFP + Flp (Figure 3H). Expression of EYFP was measurable 2 days post-injection and rapidly increased over 2 weeks, reaching 95% of maximal expression between weeks 2 and 3. Intersectional viruses co-injected with recombinases exhibited similar expression kinetics; expression rate constants for Con/Fon-EYFP, Coff/Fon-EYFP, and Con/Foff-EYFP did not differ significantly from non-recombinase-dependent control EYFP (Figure 3H, column *b*; all versus WT, WT $b = 0.1638 \pm 0.01148$, Con/Fon $b = 0.1392 \pm 0.01372$ $p = 0.4775$, Con/Foff $b = 0.1512 \pm 0.005248$ $p = 0.7728$, Coff/Fon $b = 0.1197 \pm 0.01678$ $p = 0.1380$, ANOVA with Dunnett's test, all \pm SEM). We noted a decrease in the fluorescence of Con/Foff-EYFP with high titers of Cre recombinase (after 26 days for 1×10^{11} and after 14 days for 1×10^{12} ; Figure 3H), suggesting that high viral expression of Cre is toxic. This toxicity was not observed with Cre at a titer of 1×10^{10} or with Flp or Flp-2a-Cre at a high titer (1×10^{12}). Separate cohorts with co-injections of lower titers of Con/Foff-EYFP and Cre at 1×10^{12} confirmed that this toxicity was a result of Cre expression and not intersectional virus toxicity (Figure S6E).

We also evaluated animals injected with Con/Foff-EYFP + Flp-2a-Cre or Coff/Fon-EYFP + Flp-2a-Cre. In the Coff/Fon-EYFP cohort, we found no transient, off-target expression prior to Cre inactivation of expression, highlighting the utility of chronic viral expression monitoring. In the Con/Foff-EYFP cohort, we found that the time course of low-level off-target expression with approximately equimolar expression of Cre and Flp peaked at approximately 2 weeks and slowly decayed to approximately 80% of maximum log expression at 6 weeks (data not shown). Finally, we used the cohort as an opportunity to confirm expression profiles of these intersectional viruses using a sensitive reporter (EYFP) and efficient actuator (viral recombinase). We injected separate control cohorts with EYFP intersectional viruses paired with no recombinase, AAV-Cre, AAV-Flp, or AAV-Flp-2a-Cre. We injected Cre at 1×10^{10} and 1×10^{12} titers to confirm our previous observations of toxicity with high

(B) Linear input-output relationship between total counted photons (area under the curve [AUC]) of the band-pass-filtered signal and spectrometer integration time ($R^2 = 0.9999$); spectrometer absorbance (range 0–1) and absolute photons are shown.

(C–G) Exemplar data: animal co-injected in the mPFC with AAV-Con/Fon-EYFP and AAV-Flp-2a-Cre.

(C) A wide range of spectrometer integration times ensures a continuous dynamic range (color) of non-zero and non-saturated (gray) signals from early/weak expression through late/strong expression.

(D) Linear relationship between AUC and integration time in dynamic range of the spectrometer is maintained *in vivo* (colors as in C; $R^2 = 0.9999$).

(E) Expression score: normalizing the AUC to integration time and averaging all expression scores for a given time point within the spectrometer's dynamic range; the time point from (C) and (D) is noted (arrow).


(F) Viral expression kinetics model: fit to $y = 1 - e^{-bx}$; y , normalized log expression; x , days; b , rate constant (blue dots, within-animal expression scores; red, expression curve fit; dashed, 95% confidence of fit; $b = 0.12715$, $R^2 = 0.9474$).

(G) Chronic viral monitoring does not require components beyond typical optogenetic experiments (here, a 200- μ m fiber).

(H) Comparison of WT EYFP expression versus all three INTRSECT logical expression variants of EYFP co-injected with the indicated recombinase viruses. High titers of Cre are initially expressed but cause toxicity over time (Con/Foff-EYFP + Cre, green and orange dots), which would not have been apparent without chronic monitoring. Expression kinetics between INTRSECT and non-INTRSECT EYFP viruses are equivalent (comparison of rate constant b between WT and Con/Fon $p = 0.4775$, WT and Con/Foff $p = 0.7728$, WT and Coff/Fon $p = 0.1380$, $n = 6$ animals per condition, ANOVA with Dunnett's test).

(I) Comparison of *in vivo* expression of all INTRSECT AAV-EYFP variants co-injected with all combinations of AAV recombinases as assayed by confocal fluorescence (6 weeks of expression). There was no difference between expression of WT EYFP and Con/Fon-EYFP ($p = 0.7615$, unpaired t test) or WT EYFP and Con/Foff-EYFP ($p = 0.2559$, unpaired t test). Coff/Fon-EYFP expression was lower than WT EYFP (EYFP 2.41×10^7 a.u. versus 8.96×10^6 a.u., $p = 0.0003$, unpaired t test).

See also Figures S5 and S6.



(legend on next page)

viral Cre titers. As expected, we saw consistent high expression in all viruses when paired with correct activating recombinases (Figure 3I); it is notable that AAV-Coff/Fon-EYFP expression was lower than that of control AAV-EYFP at equal viral titers ($p = 0.0003$, unpaired t test). As expected, we observed no off-target expression with AAV-Con/Fon-EYFP or AAV-Coff/Fon-EYFP with any combination of viral recombinases, whereas co-infection of Con/Foff-(FRT/F5)-EYFP with an approximately 1:1 ratio of Flp:Cre using AAV-Flp-2a-Cre exhibited modest residual expression, consistent with prior results (Figures S5D and S5E). Together, these results underscore our recommendation to use increased ratios of Flp:Cre for Con/Foff viruses while also revealing a wider tolerance of recombinase ratios for other expression logic.

We used these histologic data to further validate the *in vivo* viral monitoring device by examining the relationship between post hoc fluorescence and final *in vivo* spectroscopy expression score, taken 6 weeks post-injection (Figure S6F; $R^2 = 0.5123$, $p < 0.0001$, $n = 30$ animals, Pearson correlation). Chronic expression profiling in this way may be easily and generally applicable for biological laboratories and here reveals (at these titers) that recombinase dependence does not slow viral expression kinetics, that viral expression builds non-linearly and plateaus between the second and third weeks of expression, that intersectional virus expression is maintained for at least 6 weeks (the longest period examined), and that incorporation of an additional recombinase for next-step three-parameter targeting may be unlikely to slow experimental timelines.

New Regime of Viral Intersectionality: Triple-Recombinase-Based Targeting

As powerful as two-feature intersectional viruses have been, many meaningfully defined cellular populations might require targeting by combinations of several genetic and anatomical parameters (Poulin et al., 2018). For example, known neuronal populations defined by (1) a single genetic feature and (2) multiple axonal projection features (double-projection neurons; Jinno, 2009) are of substantial interest, although assessing the functional significance of these populations (as with the vast majority of multiple-feature-defined cell types revealed by the ongoing revolution in single-cell sequencing) remains beyond the reach of currently available molecular targeting approaches.

Although triple-recombinase dependence has not yet been achieved in single viruses, our screening of many recombinases (e.g., VCre, SCre, and Dre) for orthogonality to Flp and Cre by assaying expression of single-recombinase-dependent DIO-ChR2-EYFP constructs in flow cytometry led to identification of VCre (Suzuki and Nakayama, 2011) as the most promising potential third recombinase (Fenno et al., 2014). To create the

desired new dimension of multi-feature intersectional targeting, we therefore tested for generality of this result using cytosolic DIO-EYFP in place of membrane-localized DIO-ChR2-EYFP constructs (Figure 4A). Consistent with our previous results, we observed robust activity of Cre, Flp, Dre, and VCre when transfected along with each respective xDIO-EYFP construct (with less efficient activation exhibited by SCre); however, bi-directional, off-target activity between Cre and Dre was observed as before (Fenno et al., 2014). VCre, in contrast, was orthogonal to all of the tested recombinases (no indication of cross-activity) and, thus, found to be potentially best-suited for use in parallel with Cre and Flp. To test crucial *in vivo* functionality, we next generated AAVs for these three recombinases and corresponding xDIO-EYFP constructs and then separately injected all permutations of these constructs into mouse medial prefrontal cortex (mPFC; Figure 4B). After 4 weeks of expression, we found robust expression in subjects co-injected with the proper combinations of recombinase/xDIO-EYFP and no cross-expression in improper pairings, confirming that this combination of three recombinases is suitable for orthogonal use *in vivo*.

We then sought to create a triple intersectional construct that would only be active in cells that co-express Cre AND Flp AND VCre but not in cells with any other combination of recombinases (Figure 5A). To achieve this goal, we first leveraged the modular design of INTRSECT to create a hybrid version of our one-intron and two-intron dual-parameter constructs (Figures 1A and 1D) by inserting two introns into EYFP (Figure 5B). We utilized the engineering pipeline described here (Figure 1G) to iterate through many variants with the introns placed at different locations (Figure 5C) because incorporating multiple introns into EYFP itself was non-trivial and resulted in a high degree of mis-splicing. As expected, splicing efficiency was accurately reflected in EYFP expression levels of HEK293 cells quadruple-transfected with the three recombinases and Con/Fon/VCon-EYFP variants (Figure 5D). Through this iterative approach, we identified a variant with excellent expression (hereafter called 3x-EYFP). We next performed flow cytometry of HEK293 cells co-transfected with various combinations of recombinases and the triple-dependent INTRSECT (Triplesect) construct and confirmed that expression of 3x-EYFP was limited to cells co-expressing all three recombinases (Figure 5E). We tested the specificity of 3x-EYFP expression *in vivo* by injecting the mPFC of mice with AAV-3x-EYFP and combinations of AAV recombinases, confirming strong specific expression of this novel Triplesect virus only in cells co-expressing Cre, Flp, and VCre (Figure 5F).

Having created a proof-of-concept, triple-recombinase-dependent EYFP and confirmed its specific, strong expression *in vivo*, we next asked whether this targeting approach

Figure 4. Identifying and Validating a Recombinase Orthogonal to Cre and Flp

(A) Flow cytometry of HEK293 cells co-transfected with combinations of recombinase expression constructs (rows) and recombinase-dependent EYFP constructs (xDIO-EYFP, columns). Cre and Dre showed bi-directional cross-activity, and some cross-activity was noted when Cre was paired with scDIO-EYFP. VCre showed the expected robust action on its vcDIO-EYFP partner without any noted *in vitro* cross-activity.
(B) AAV-Cre, AAV-Flp, and AAV-VCre showed expected robust activity when co-injected with their partner AAV-xDIO-EYFP without cross-activity after 4 weeks of expression in the mPFC; low (left) and high (right) magnification. Needle track was used to identify injection sites in samples without expression.
(C) rAAV serotypes of Flp and VCre co-injected with respective AAV-xDIO-EYFP in the mPFC while also injecting AAV-xDIO-EYFP into the VTA. After 2 weeks (left), sparse EYFP expression was observed in the mPFC and VTA, and at 4 weeks, high levels of expression in both sites (right).




Figure 5. Engineering, Optimization, Testing, and *In Vivo* Function of Three-Recombinase-Dependent Triplesect Constructs

(A) Potential intersectional populations available with three-recombinase expression. The Cre AND Flp AND VCre intersectional population is denoted by a central pattern.

(B) Detailed diagram of EYFP divided into three exons with addition of two introns and recombinase recognition sites (top). The activity of Cre AND Flp AND VCre reorients exons in the sense direction (center). Introns are removed during RNA processing (bottom), ending with an intact mRNA encoding EYFP; we labeled this three-recombinase-dependent approach 3x-EYFP.

(C and D) We generated multiple 3x-EYFP construct variants with different intron placement.

(C) Variants 1–3 spliced poorly, whereas variant 4 spliced efficiently, as verified by sequencing (bottom).

(D) Splicing results mirrored expression patterns in HEK293 cells co-transfected with 3x-EYFP variants and Cre, Flp, and VCre. We therefore used variant 4 going forward.

(E and F) No expression of 3x-EYFP was observed when any of the three recombinases was missing, as assayed by flow cytometry of HEK293 cells (E) or in animals injected with 3x-EYFP and recombinases (F; $n = 1$ –2 animals per condition).

(G–K) 3x engineering approach applied to the calcium sensor GCaMP6m (3x-G6m): a similar pattern of proper intron splicing (G) and lack of off-target expression by flow cytometry of HEK293 cells (H; coloring as in E).

(legend continued on next page)

(Triplesect) would be generalizable and would, for example, allow creation of a 3 \times -GCaMP6m. As with 3 \times -EYFP, 3 \times -GCaMP6m spliced efficiently (Figure 5G) and was only expressed when co-transfected with all three recombinases (Figure 5H). We verified functionality of 3 \times -GCaMP6m in cultured neurons (Figure 5I). To assess *in vivo* function and specificity of our 3 \times expression platform, we next co-injected AAV-3 \times -GCaMP6m and combinations of recombinases into the ventral tegmental area (VTA) of TH^{tm(Cre)} (TH-Cre) transgenic mice and inserted 400 μ m fiberoptic implants to conduct fiber photometry during novel object exploration (Gunaydin et al., 2014). Consistent with our previous Triplesect results (Figure 5F), robust Ca²⁺ signals were observed in animals co-expressing all three recombinases (Figure 5J, orange) but not in animals expressing only two recombinases (Figure 5J, green, purple, and blue). 3 \times -GCaMP6m animals expressing all three recombinases showed consistent, time-locked Ca²⁺ transients beginning immediately prior to periods of novel object exploration, which was not seen in animals expressing only two of these recombinases (Figure 5J, blue bars, Figure 5K). Histology (Figure 5L) of 3 \times -GCaMP6m animals was consistent with the photometry, showing no expression in control subjects but the expected VTA expression pattern in three-recombinase animals. The Triplesect approach and the intron-engineering pipeline described here thus define a generalizable approach to creation and testing of versatile tools for probing cell types with a new dimension of precision and specificity *in vivo* and in behaving animals.

DISCUSSION

Experimental capabilities for cell-type-specific delivery of function-testing tools (such as genetically encoded Ca²⁺ indicators and microbial opsins) have not kept pace with the insights and opportunities afforded by single-cell transcriptomics and connectomics. As a result, the ongoing revolution in cellular-resolution molecular phenotyping has remained largely passive and descriptive. Here, we (1) developed a comprehensive toolbox for precision viral targeting of cells based on dual-parameter logic using a standardized algorithmic engineering pipeline, bringing the total number of INTRASECT viruses to 45, now including a wide array of optically modulated molecular payloads; (2) demonstrated improved recombinase efficiency for specific logical configurations found through a rational screen utilizing functional criteria; (3) implemented

in vivo viral expression-monitoring hardware suitable for widespread use in biology laboratories; and (4) described the first triple-parameter single-virus targeting logic through creation of Triplesect.

The Intersectional Pipeline

By creating the pipeline, we sought to deliver intersectionally targetable tools (Fenno et al., 2011, 2014) covering a wide range of actuation wavelengths, biophysical mechanisms, and temporal kinetics, including fluorophores ranging from blue to red, multiple excitatory opsins paired with different fluorophores, a range of inhibitory opsins, and Ca²⁺ indicators with different excitation wavelengths and temporal dynamics. The engineering pipeline was designed to reveal flaws early (including minor splice variants and inefficiency of Flp relative to Cre; Figures 2 and S5) and ensure that each tool would function appropriately. In the work reported here, splice variants were corrected or, where persistent, demonstrated to have no adverse effects on function.

The relative inefficiency of Flp constrains the utility of all combinatorial systems using Flp, motivating our substantial effort to screen for and improve Flp-dependent components of the intersectional backbone (complementing previous work to improve the function of Flp recombinase itself; Buchholz et al., 1998; Raymond and Soriano, 2007). Although this screen yielded an approximately 20% improvement in Flp efficiency in the FRT/F5-based constructs compared with our initial design, it is likely that more efficient Flp-responsive elements (e.g., FRT sequence variants) or improved Flp recombinase variants may be developed in the future to further expand the utility of the intersectional virus approach. Additional approaches not yet tested include decreasing efficiency of Cre (possibly through the use of less efficient lox sequence variants to match the recombination kinetics of the two recombinases; Ringrose et al., 1998) and incorporating novel recombinase recognition sites that are less prone to spontaneous recombination (Fischer et al., 2019).

Ongoing Within-Mouse Expression Tracking *In Vivo*

The known difference in efficiency between recombinases motivated our development of a robust device that could be used broadly across biological laboratories, including groups not specialized in optical methodologies. To test whether factors such as recombinase dependence of intersectional tools or variable recombinase efficiency changed the rate of payload expression *in vivo*, we developed a novel, inexpensive fiberoptic

(I) *In vitro* function of quadruple-transfected (with Cre, Flp, and VCre) neurons expressing 3 \times -G6m with electrical field stimulation. Population comparison of 3 \times -G6m versus WT G6m showed reliable function but with a reduced basal fluorescence level (time to peak: 0.3727 ± 0.03938 versus 0.282 ± 0.01359 , $p = 0.0045$; signal-to-noise ratio: 25.01 ± 2.733 versus 15.72 ± 1.66 , $p = 0.0080$; dF/F: 0.2646 ± 0.03951 versus 0.0466 ± 0.007635 , $p < 0.0001$; basal fluorescence: 280.6 ± 48.05 versus 2141 ± 337.2 , $p < 0.0001$; tau: 1.15 ± 0.1112 versus 1.736 ± 0.1179 , $p = 0.0001$. 3 \times -G6m, $n = 32$; WT, $n = 43$; all mean \pm SEM; Mann-Whitney test). (J–L) Co-infection of the TH-Cre mouse VTA with 3 \times -G6m and separate viruses encoding Flp and VCre gave rise to robust calcium signals during novel object exploration (J; orange) but not in animals co-infected with 3 \times -G6m and combinations of only two recombinases (green, purple, and blue). (K) Average Ca²⁺ signal from traces in (J) time-locked to onset of novel object exploration (left) shows a consistent signal from 3 \times -G6m with all three recombinases but no signal in two-recombinase controls (total object interactions orange trace = 32, green trace = 27, purple trace = 32, blue trace = 42). Center: shuffling the bout onset times while maintaining the bout structure in this same trace showed that the observed signal was not due to random fluctuation ($p < 0.01$). Right: average peak signal from traces in (K) as well as additional three-recombinase-expressing animals (Cre and Flp and VCre active condition versus each two-recombinase control $p < 0.0001$, ANOVA with Dunnett's test). (L) Exemplary slice images (left) and quantification (right) from mice in (J): expression of 3 \times -G6m only ($n = 3$ mice) when all three recombinases are expressed but not in two-recombinase control mice (Cre and Flp and VCre active condition versus each two-recombinase control $p < 0.05$, ANOVA with Dunnett's test; $n = 3$ sections/mouse, 1 mouse in each of 3 controls, 3 mice in triple-recombinase).

device for chronic expression monitoring, using off-the-shelf commercially available components. More complex larger-fiber neuroscience-specialized systems (e.g., fiber photometry hardware; Gunaydin et al., 2014) could acquire similar data; however, the system described here is likely to be more broadly useful across biological systems spanning organisms and tissues and will be generally useful for screening experimental subjects prior to behavioral experiments to assay steady-state expression, proper interventional (optogenetic) fiber placement, and/or virus efficacy (especially in unique and valuable individual subjects such as non-human primates; Diester et al., 2011).

Our finding that recombinase- and non-recombinase-dependent AAV8 expression tracked previous histology-based expression profiling (Klein et al., 2006; Reimsnider et al., 2007) validated this approach and provided useful quantitative new tool characterization. Importantly, recombinase dependence of the intersectional tools at these viral titers was found to not slow expression *in vivo*. Additional characterization of other serotypes, payloads, and titers will build further knowledge of critical (and generally unknown) parameters of viral expression in organs and species across biology.

Triplesect

To extend targeting resolution to three-parameter dependence, VCre (Suzuki and Nakayama, 2011) was chosen over other tested recombinases for superior orthogonality to Cre and Flp in multiple expression platforms, with multiple payloads, and as evaluated with two separate assays for cross-expression (one *in vitro* and the other *in vivo*); the bi-directional cross-activity of Dre (with Cre) as well as the poor efficiency of SCre were consistent with prior work (Weinberg et al., 2017). Here the demonstration of three-recombinase-dependent viral expression (Triplesect) marks a new level of viral targeting specificity (*in vitro* or *in vivo*); going forward, additional recombinase/recombination sites, including Nigri/nox and Panto/pox (Karimova et al., 2016), may show promise as potential additional orthogonal recombinases for complementary targeting approaches.

Animal Platforms for Intersectional Biology

Triplesect and the intersectional tool set leverage the expanding availability of Flp recombinase and other transgenic mouse lines (Daigle et al., 2018; Karimova et al., 2018; Madisen et al., 2015; Plummer et al., 2015). From an experimental design perspective, single-virus targeting offers multiple advantages over use of multiply crossed, intersectional transgenics. First, viruses are restricted in time and space, avoiding potential off-target expression because of transient gene expression during development and allowing expression only within specified anatomic regions of interest (Poulin et al., 2018). In addition, viruses also afford an opportunity for simultaneous expression of multiple intersectionally expressed, molecular tools in the same anatomic space for co-labeling, an approach that would generally require a prohibitive animal husbandry effort to replicate with a purely transgenic approach. Last, the viral tools provide a vast increase in resource efficiency because the dissociation of cell targeting and molecular tool identity allows a single recombinase-expressing transgenic mouse line to be paired with an unlimited variety of virally delivered tools.

The intersectional viruses described here are designed to be integrated with any combination of molecular tool and recombinase expression. However, one limitation in fully integrating the diversity of Flp-expressing animal lines with intersectional tools is the lack of a centralized database of these animal lines. To facilitate a wide range of two-parameter (e.g., Cre/Flp double-transgenic) and three-parameter Triplesect experimental designs (e.g., Cre/Flp double transgenics with additional recombinases delivered by local or retrograde virus; Figure 4C), we created such a database (Table 1). We searched academic publications, commercial mouse repositories, and publicly funded transgenic efforts to inventory currently reported and still unpublished Flp-expressing mouse lines. We identified 60 mouse lines that represent a total of 47 separate genetic drivers and one transgenic rat line. Of these, five different lines have already been used experimentally with INTRASECT viruses. To ensure the ongoing usefulness of this resource, we created a web-based version that includes the ability for researchers to submit data (http://www.optogenetics.org/flp_lines.html).

General Considerations for Experimental Design with Intersectional Viruses

AAV has become the standard for gene transduction *in vivo*, including in neuroscience because of the relative safety of the DNA genome and ease of production and engineering. A feature of AAVs salient to experimental design is viral tropism—the ability of viruses to transduce a subset of cells based on the expression of a viral receptor specific to viral serotype—here referring to the capsid protein that interacts with the receptor. AAVs are now routinely produced in a number of serotypes; throughout this study, we used AAV8 and a synthetic retro-AAV (evolved to transduce axon terminals; Tervo et al., 2016). The identity of cells infected by a particular AAV is affected by AAV serotype (Aschauer et al., 2013; Burger et al., 2004; Davidson et al., 2000), developmental time point (Chakrabarty et al., 2013), animal strain (Hordeaux et al., 2018), and viral titer (Nathanson et al., 2009). Despite the critical role of AAVs in modern biology, a broad accounting of cell subtype transducibility influenced by these parameters has not been described, although it is conceivable that this information may be extracted (Cristinelli and Ciuffi, 2018) from existing transcriptome datasets (Ecker et al., 2017) utilizing a combination of AAV transduction and single-cell RNA sequencing (RNA-seq).

For viral and transgenic intersectional approaches, imperfections in reagents (e.g., specificity and sensitivity of recombinase expression, an important consideration even between separate knockin animal lines encoding the same transgene at the same locus; Madisen et al., 2010) are multiplicative, and independent knowledge that the selected viral tropism and recombinase expression pattern appropriately recruit the subpopulation of interest is critical. Control experiments co-injecting viruses that require only Cre or only Flp to be activated and assaying the expression pattern by histological evaluation is one way to obtain this critical validation. Characterization of recombinase expression patterns using only antibody or *in situ* data on the recombinase itself will not give information about viral transducibility but still serves as an important complementary control.

Table 1. Transgenic Flp Mouse Lines for Intersectional Biology

Driver	Flp Gene	Genetics	Source	Original Citation	INTRSECT Citation
Actb	FlpE	A	Jackson: 003800	Rodríguez et al., 2000	N/A
Atoh1	FlpO-ER	A	joynera@mskcc.org	Wojcinski et al., 2019	N/A
Bhlhe22	FlpO	C	saross@pitt.edu	Cai et al., 2016	N/A
Cag	FlpE	A	RBRC: 10707, 10708	Kanki et al., 2006	N/A
Cag	FlpE-ER	A	no longer maintained	Hunter et al., 2005	N/A
CamK2a	FlpE	N/A	Taconic, not available	N/A	N/A
Cdx2	FlpO	A	Jackson: 030288	Abraira et al., 2017	N/A
Cdx2	FlpO	A	goulding@salk.edu	Britz et al., 2015	N/A
Crh	FlpO	D	Jackson: 031559	unpublished	N/A
DbH	FlpO	C	Jackson: 033952	Robertson et al., 2013	N/A
DbH	FlpO	C	MMRRC: 41577	Sun and Ray, 2016	N/A
DbH	FlpO	E	MMRRC: 41575	Sun and Ray, 2016	N/A
Dlx5/6	Myc-FlpE	A	Jackson: 010815	Miyoshi et al., 2010	Christenson Wick et al., 2019
EF1A	Flp	A	RBRC: 01251, 01252	Takeuchi et al., 2002	N/A
Fezf2	FlpO	E	huangj@cshl.edu	Matho et al., 2020	N/A
Gad2	FlpO	D	hantmana@janelia.hhmi.org	Alhadeff et al., 2018	N/A
GFAP	FlpO	A	Jackson: 33116	Hara and Verma, 2019	N/A
Gsh2	FlpE	D	CARD: 2114	S. Esumi, personal communication	N/A
Hcrt	FlpO	E	yamank@riem.nagoya-u.ac.jp	Chowdhury et al., 2019	N/A
Hoxb8	FlpO	A	EMMA: 11094	Zhang et al., 2018	N/A
Htr3a	FlpO	D	Jackson: 030755	Schuman et al., 2019	N/A
Lbx1	FlpO	C	goulding@salk.edu	Bourane et al., 2015	N/A
mGluR6	FlpO	A	RBRC: 09715	unpublished	N/A
MMTV	FlpO	A	gerhard.christofori@unibas.ch	Lüönd et al., 2019	N/A
Mrgprb4	EGFP-2a-FlpO	F	Jackson: 021078	Vrontou et al., 2013	N/A
Nestin	FlpO-ER	A	joynera@mskcc.org	Lao et al., 2012	N/A
Nkx2.1	FlpO	D	Jackson: 28577	He et al., 2016	N/A
Nphs1	FlpO	A	minerj@wustl.edu	Goldberg et al., 2010	N/A
Npy	FlpO	D	Jackson: 030211	Daigle et al., 2018	N/A
Pdx1	FlpO	A	dieter.saur@tum.de	Schönhuber et al., 2014	N/A
Pdx1	FlpO	C	ostrowsk@muscc.edu	Wu et al., 2017	N/A
Pet1	FlpE	A	dymecki@genetics.med.harvard.edu	Jensen et al., 2008	N/A
Pgk1	FlpO	A	Jackson: 011065	Wu et al., 2009	N/A
Phox2b	FlpO	B	Jackson: 022407	Hirsch et al., 2013	N/A
Prkcd	FlpO	E	bli@cshl.edu	B. Li, personal communication	N/A
PlexinD1	FlpO	E	huangj@cshl.edu	Matho et al., 2020	N/A
Plxnd1	dgFlpO	D	tanyad@alleninstitute.org	Daigle et al., 2018	N/A
Pomc	FlpE	A	no longer maintained	Vooijs et al., 1998	N/A
Pvalb	FlpE	E	Jackson: 021191	Madisen et al., 2015	N/A
Pvalb	FlpO	E	Jackson: 022730	Madisen et al., 2015	Hafner et al., 2019
Pvalb ^a	FlpO	E	joshua.berke@ucsf.edu	Yu et al., 2018	N/A
Rasgrf2	dgFlpO	E	Jackson: 029589	Daigle et al., 2018	N/A
Rorb	FlpO	D	Jackson: 029590	Daigle et al., 2018	N/A
Rorb	FlpO	E	tanyad@alleninstitute.org	Daigle et al., 2018	N/A
Slc17a6	FlpO	D	Jackson: 030212	Daigle et al., 2018	N/A
Slc32a1	FlpO	D	Jackson: 031331	Daigle et al., 2018	N/A

(Continued on next page)

Table 1. Continued

Driver	Flp Gene	Genetics	Source	Original Citation	INTRSECT Citation
Slc32a1	FlpO	E	Jackson: 029591	Daigle et al., 2018	Lazaridis et al., 2019
Slc6a3	FlpO	D	Jackson: 033673	unpublished	N/A
Slc6a4	FlpO	D	Jackson: 033674	unpublished	N/A
SST	FlpO	D	Jackson: 028579	He et al., 2016	Clemente-Perez et al., 2017; Cummings and Clem, 2020; Fadok et al., 2017; Fenno et al., 2014; Yu et al., 2017
Tbr2	FlpO-ER	E	huangj@cshl.edu	Matho et al., 2020	N/A
Tbx21	FlpE-ER	D	Graham.lord@manchester.ac.uk	Gökmen et al., 2013	N/A
TH	FlpO	E	MMRRC: 50618	Poulin et al., 2018	Chuhma et al., 2018 Poulin et al., 2018 Mingote et al., 2019
TH	FlpO	A	RBRC: 5168-5171	Imayoshi et al., 2012	N/A
Trf	FlpE	N/A	Taconic, not available	N/A	N/A
Tshz1	FlpO	E	bli@cshl.edu	B. Li, personal communication	N/A
VGlut2	FlpO	D	hantmana@janelia.hhmi.org	Alhadeff et al., 2018	N/A
VIP	FlpO	D	Jackson: 028578	He et al., 2016	N/A
Wnt1	Flp(F70L)	A	no longer maintained	Dymecki and Tomasiewicz, 1998	N/A
Wnt1	FlpE-ER	A	no longer maintained	Hunter et al., 2005	N/A
Wnt1	FlpE	A	dymecki@genetics.med.harvard.edu	Awatramani et al., 2003	N/A

Transgenic lines were located via a range of search methods. Lines no longer maintained are included for completeness. Any reference to contact individuals was approved. An online version with functionality to add lines is maintained at http://www.optogenetics.org/flp_lines.html. A, random integration; B, bacterial artificial chromosome (BAC) transgenic; C, start codon knockin; D, internal ribosomal entry site (IRES) knockin; E, 2a knockin; F, 2a knockin/driver knock-out; Jackson, Jackson Laboratory (<https://www.jax.org/>); RBRC: Riken BioResource Research Center (<https://mus.brc.riken.jp/en/>); MMRRC, Mutant Mouse Resource and Research Centers (<https://www.mmrrc.org/>); CARD, Center for Animal Resources and Development (<http://cardb.cc.kumamoto-u.ac.jp/transgenic/index.jsp>); EMMA, European Mouse Mutant Archive (<https://www.infrafrontier.eu/>).

^aTransgenic rat line.

Understanding and characterizing the limitations of these (and any other) tools is a critical component of successful experimental design and interpretation. Here we describe the function of the intersectional toolbox using a variety of platforms *in vitro* and *in vivo*. To assist users with designing experiments and important controls to consider, we maintain a freely available resource (http://www.optogenetics.org/intrsect_sop.pdf), updated in response to feedback from the community, that also describes common pitfalls we and others have experienced when scaling and implementing recombinase-based systems (Figure 2H).

Further extending the precision with which biologists are able to functionally interrogate cell populations is critical and becoming more important as the field progresses. Going forward, strategies such as iterative improvement of Con/Off constructs, incorporation of additional molecular tools (Hafner et al., 2019; Platt et al., 2014; Villette et al., 2019), and extension to multiple-recombinase-dependent RNA polymerase III (Ventura et al., 2004; Yu and McMahon, 2006) expression will continue to push boundaries of intersectional experimental design. In this way, our rapidly advancing ability to describe cell types through multimodal data streams integrating single-cell gene

expression with developmental (Asp et al., 2019; Petropoulos et al., 2016), anatomical (Codeluppi et al., 2018; Satija et al., 2015), subcellular (Chen et al., 2015), and three-dimensional architectural (Wang et al., 2018) features at high resolution may become accompanied by an improved capability to investigate the functional relevance of these cell types to health or disease in living systems.

STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- RESOURCE AVAILABILITY
 - Lead Contact
 - Materials Availability
 - Data and Code Availability
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
 - Animals
 - Flp Line Database
 - Primary Neuronal Cell Cultures

- HEK293 Cell Cultures
- **METHOD DETAILS**
 - Molecular cloning
 - sRGECO and oScarlet development
 - mRNA isolation and cDNA synthesis
 - Flow cytometry
 - Primary Neuron Culture Transfection
 - Primary Culture Electrophysiology
 - Cultured Neuron Calcium Imaging
 - Virus production
 - Stereotactic injections
 - Slice electrophysiology
 - Spectrophotometry and Viral Kinetic Analysis
 - Fiber Photometry
 - Histology
- **QUANTIFICATION AND STATISTICAL ANALYSIS**
 - Additional Resources

SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at <https://doi.org/10.1016/j.neuron.2020.06.003>.

ACKNOWLEDGMENTS

We thank Meredith Weglarz at the Stanford FACS Facility, the Stanford Department of Statistics, and Ethan Richman for assistance with bio-statistics and Javier Fernandez-Alcudia and the Stanford Gene Vector and Virus Core for virus production. S.V. received support from the NSF, Y.S.K. from Stanford Bio-X and the Kwanjeong Fellowship, L.E.F. from NIMH and Stanford Psychiatry, and K.D. from the NSF, NIH, DARPA, Gatsby Foundation, NOMIS Foundation, Wieggers Foundation, Tarlton Foundation, and Fresenius Foundation.

AUTHOR CONTRIBUTIONS

Conceptualization, L.E.F., C.R., Y.S.K., and K.D.; Methodology, L.E.F., C.R., Y.S.K., and S.V.; Software, L.E.F. and S.V.; Formal Analysis, L.E.F., Y.S.K., S.V., and M.I.; Experimental Investigation, L.E.F., C.R., Y.S.K., K.E.E., M.L., S.V., M.I., K.Y.M.C., E.Y., N.P., and A.S.O.H.; Visualization, L.E.F. and Y.S.K.; Writing, L.E.F., C.R., Y.S.K., and K.D.; Supervision, K.D.

DECLARATION OF INTERESTS

The authors declare no competing interests.

Received: March 20, 2020

Revised: May 8, 2020

Accepted: May 29, 2020

Published: June 22, 2020

SUPPORTING CITATIONS

The following references appear in the Supplemental Information: Berndt et al. (2016).

REFERENCES

Abraira, V.E., Kuehn, E.D., Chirila, A.M., Springel, M.W., Toliver, A.A., Zimmerman, A.L., Orefice, L.L., Boyle, K.A., Bai, L., Song, B.J., et al. (2017). The cellular and synaptic architecture of the mechanosensory dorsal horn. *Cell* 168, 295–310.e19.

Alhadeff, A.L., Su, Z., Hernandez, E., Klima, M.L., Phillips, S.Z., Holland, R.A., Guo, C., Hantman, A.W., De Jonghe, B.C., and Betley, J.N. (2018). A Neural

Circuit for the Suppression of Pain by a Competing Need State. *Cell* 173, 140–152.e15.

Andrews, B.J., Proteau, G.A., Beatty, L.G., and Sadowski, P.D. (1985). The FLP recombinase of the 2 micron circle DNA of yeast: interaction with its target sequences. *Cell* 40, 795–803.

Aschauer, D.F., Kreuz, S., and Rumpel, S. (2013). Analysis of transduction efficiency, tropism and axonal transport of AAV serotypes 1, 2, 5, 6, 8 and 9 in the mouse brain. *PLoS ONE* 8, e76310.

Asp, M., Giacomello, S., Larsson, L., Wu, C., Fürth, D., Qian, X., Wärdell, E., Custodio, J., Reimegård, J., Salmén, F., et al. (2019). A Spatiotemporal Organ-Wide Gene Expression and Cell Atlas of the Developing Human Heart. *Cell* 179, 1647–1660.e19.

Atasoy, D., Aponte, Y., Su, H.H., and Sternson, S.M. (2008). A FLEX switch targets Channelrhodopsin-2 to multiple cell types for imaging and long-range circuit mapping. *J. Neurosci.* 28, 7025–7030.

Awatramani, R., Soriano, P., Rodriguez, C., Mai, J.J., and Dymecki, S.M. (2003). Cryptic boundaries in roof plate and choroid plexus identified by inter-sectional gene activation. *Nat. Genet.* 35, 70–75.

Berndt, A., Lee, S.Y., Wietek, J., Ramakrishnan, C., Steinberg, E.E., Rashid, A.J., Kim, H., Park, S., Santoro, A., Frankland, P.W., et al. (2016). Structural foundations of optogenetics: Determinants of channelrhodopsin ion selectivity. *Proc. Natl. Acad. Sci. USA* 113, 822–829.

Bindels, D.S., Haarbosch, L., van Weeren, L., Postma, M., Wiese, K.E., Mastop, M., Aumonier, S., Gotthard, G., Royant, A., Hink, M.A., and Gadella, T.W., Jr. (2017). mScarlet: a bright monomeric red fluorescent protein for cellular imaging. *Nat. Methods* 14, 53–56.

Bourane, S., Duan, B., Koch, S.C., Dalet, A., Britz, O., Garcia-Campmany, L., Kim, E., Cheng, L., Ghosh, A., Ma, Q., et al. (2015). Gate control of mechanical itch by a subpopulation of spinal cord interneurons. *Science* 350, 550–554.

Britz, O., Zhang, J., Grossmann, K.S., Dyck, J., Kim, J.C., Dymecki, S., Gosgnach, S., and Goulding, M. (2015). A genetically defined asymmetry underlies the inhibitory control of flexor–extensor locomotor movements. *eLife* 4, e04718.

Brunak, S., Engelbrecht, J., and Knudsen, S. (1991). Prediction of human mRNA donor and acceptor sites from the DNA sequence. *J. Mol. Biol.* 220, 49–65.

Buchholz, F., Angrand, P.O., and Stewart, A.F. (1998). Improved properties of FLP recombinase evolved by cycling mutagenesis. *Nat. Biotechnol.* 16, 657–662.

Burger, C., Gorbatyuk, O.S., Velardo, M.J., Peden, C.S., Williams, P., Zolotukhin, S., Reier, P.J., Mandel, R.J., and Muzyczka, N. (2004). Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. *Mol. Ther.* 10, 302–317.

Cai, X., Kardon, A.P., Snyder, L.M., Kuzirian, M.S., Minestro, S., de Souza, L., Rubio, M.E., Maricich, S.M., and Ross, S.E. (2016). Bhlhb5:flpo allele uncovers a requirement for Bhlhb5 for the development of the dorsal cochlear nucleus. *Dev. Biol.* 414, 149–160.

Chakrabarty, P., Rosario, A., Cruz, P., Sieminski, Z., Ceballos-Diaz, C., Crosby, K., Jansen, K., Borchelt, D.R., Kim, J.-Y., Jankowsky, J.L., et al. (2013). Capsid serotype and timing of injection determines AAV transduction in the neonatal mice brain. *PLoS ONE* 8, e67680.

Chen, K.H., Boettiger, A.N., Moffitt, J.R., Wang, S., and Zhuang, X. (2015). RNA Imaging. Spatially resolved, highly multiplexed RNA profiling in single cells. *Science* 348, aaa6090.

Chowdhury, S., Hung, C.J., Izawa, S., Inutsuka, A., Kawamura, M., Kawashima, T., Bito, H., Imayoshi, I., Abe, M., Sakimura, K., and Yamanaka, A. (2019). Dissociating orexin-dependent and -independent functions of orexin neurons using novel Orexin-Flip knock-in mice. *eLife* 8, e44927.

Christenson Wick, Z., Tetzlaff, M.R., and Krook-Magnuson, E. (2019). Novel long-range inhibitory nNOS-expressing hippocampal cells. *eLife* 8, e46816.

Chuhma, N., Mingote, S., Yetnikoff, L., Kalmbach, A., Ma, T., Ztaou, S., Sienna, A., Tepler, S., Poulin, J., Ansorge, M., et al. (2018). Dopamine neuron

glutamate cotransmission evokes a delayed excitation in lateral dorsal striatal cholinergic interneurons. *eLife* 7, e39786.

Clemente-Perez, A., Ritter Makinson, S., Higashikubo, B., Brovarno, S., Cho, F.S., Urry, A., Holden, S.S., Wimer, M., Dávid, C., Fenno, L.E., et al. (2017). Distinct Thalamic Reticular Cell Types Differentially Modulate Normal and Pathological Cortical Rhythms. *Cell Rep.* 19, 2130–2142.

Codeluppi, S., Borm, L.E., Zeisel, A., La Manno, G., van Lunteren, J.A., Svensson, C.I., and Linnarsson, S. (2018). Spatial organization of the somatosensory cortex revealed by osmFISH. *Nat. Methods* 15, 932–935.

Cristinelli, S., and Ciuffi, A. (2018). The use of single-cell RNA-Seq to understand virus-host interactions. *Curr. Opin. Virol.* 29, 39–50.

Cummings, K.A., and Clem, R.L. (2020). Prefrontal somatostatin interneurons encode fear memory. *Nat. Neurosci.* 23, 61–74.

Daigle, T.L., Madisen, L., Hage, T.A., Valley, M.T., Knoblich, U., Larsen, R.S., Takeno, M.M., Huang, L., Gu, H., Larsen, R., et al. (2018). A Suite of Transgenic Driver and Reporter Mouse Lines with Enhanced Brain-Cell-Type Targeting and Functionality. *Cell* 174, 465–480.e22.

Dana, H., Mohar, B., Sun, Y., Narayan, S., Gordus, A., Hasseman, J.P., Tsegaye, G., Holt, G.T., Hu, A., Walpita, D., et al. (2016). Sensitive red protein calcium indicators for imaging neural activity. *eLife* 5, e12727.

Davidson, B.L., Stein, C.S., Heth, J.A., Martins, I., Kotin, R.M., Derksen, T.A., Zabner, J., Ghodsi, A., and Chiorini, J.A. (2000). Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. *Proc. Natl. Acad. Sci. USA* 97, 3428–3432.

Diester, I., Kaufman, M.T., Mogri, M., Pashae, R., Goo, W., Yizhar, O., Ramakrishnan, C., Deisseroth, K., and Shenoy, K.V. (2011). An optogenetic toolbox designed for primates. *Nat. Neurosci.* 14, 387–397.

Ding, J., Luo, A.F., Hu, L., Wang, D., and Shao, F. (2014). Structural basis of the ultrasensitive calcium indicator GCaMP6. *Sci. China Life Sci.* 57, 269–274.

Dymecki, S.M., and Tomasiewicz, H. (1998). Using Flp-recombinase to characterize expansion of Wnt1-expressing neural progenitors in the mouse. *Dev. Biol.* 201, 57–65.

Ecker, J.R., Geschwind, D.H., Kriegstein, A.R., Ngai, J., Osten, P., Polioudakis, D., Regev, A., Sestan, N., Wickersham, I.R., and Zeng, H. (2017). The BRAIN Initiative Cell Census Consortium: Lessons Learned toward Generating a Comprehensive Brain Cell Atlas. *Neuron* 96, 542–557.

Fadok, J.P., Krabbe, S., Markovic, M., Courtin, J., Xu, C., Massi, L., Botta, P., Bylund, K., Müller, C., Kovacevic, A., et al. (2017). A competitive inhibitory circuit for selection of active and passive fear responses. *Nature* 542, 96–100.

Fenno, L., Yizhar, O., and Deisseroth, K. (2011). The development and application of optogenetics. *Annu. Rev. Neurosci.* 34, 389–412.

Fenno, L.E., Mattis, J., Ramakrishnan, C., Hyun, M., Lee, S.Y., He, M., Tucciarone, J., Selimbeyoglu, A., Berndt, A., Grosenick, L., et al. (2014). Targeting cells with single vectors using multiple-feature Boolean logic. *Nat. Methods* 11, 763–772.

Fenno, L.E., Mattis, J., Ramakrishnan, C., and Deisseroth, K. (2017). A guide to creating and testing new INTRSECT constructs. *Curr. Protoc. Neurosci.* 80, 4.39.1–4.39.24.

Fischer, K.B., Collins, H.K., and Callaway, E.M. (2019). Sources of off-target expression from recombinase-dependent AAV vectors and mitigation with cross-over insensitive ATG-out vectors. *Proc. Natl. Acad. Sci. U.S.A.* 116, 27001–27010.

Gao, Z.R., Chen, W.Z., Liu, M.Z., Chen, X.J., Wan, L., Zhang, X.Y., Yuan, L., Lin, J.K., Wang, M., Zhou, L., et al. (2019). Tac1-Expressing Neurons in the Periaqueductal Gray Facilitate the Itch-Scratching Cycle via Descending Regulation. *Neuron* 101, 45–59.e9.

Gökmen, M.R., Dong, R., Kanhere, A., Powell, N., Perucha, E., Jackson, I., Howard, J.K., Hernandez-Fuentes, M., Jenner, R.G., and Lord, G.M. (2013). Genome-wide regulatory analysis reveals that T-bet controls Th17 lineage differentiation through direct suppression of IRF4. *J. Immunol.* 191, 5925–5932.

Goldberg, S., Adair-Kirk, T.L., Senior, R.M., and Miner, J.H. (2010). Maintenance of glomerular filtration barrier integrity requires laminin $\alpha 5$. *J. Am. Soc. Nephrol.* 21, 579–586.

Gradinaru, V., Zhang, F., Ramakrishnan, C., Mattis, J., Prakash, R., Diester, I., Goshen, I., Thompson, K.R., and Deisseroth, K. (2010). Molecular and cellular approaches for diversifying and extending optogenetics. *Cell* 141, 154–165.

Gunaydin, L.A., Grosenick, L., Finkelstein, J.C., Kauvar, I.V., Fenno, L.E., Adhikari, A., Lammel, S., Mirzabekov, J.J., Airan, R.D., Zalocusky, K.A., et al. (2014). Natural neural projection dynamics underlying social behavior. *Cell* 157, 1535–1551.

Hafner, G., Witte, M., Guy, J., Subhashini, N., Fenno, L.E., Ramakrishnan, C., Kim, Y.S., Deisseroth, K., Callaway, E.M., Oberhuber, M., et al. (2019). Mapping Brain-Wide Afferent Inputs of Parvalbumin-Expressing GABAergic Neurons in Barrel Cortex Reveals Local and Long-Range Circuit Motifs. *Cell Rep.* 28, 3450–3461.e8.

Hara, T., and Verma, I.M. (2019). Modeling gliomas using two recombinases. *Cancer Res.* 79, 3983–3991.

He, M., Tucciarone, J., Lee, S., Nigro, M.J., Kim, Y., Levine, J.M., Kelly, S.M., Krugikov, I., Wu, P., Chen, Y., et al. (2016). Strategies and Tools for Combinatorial Targeting of GABAergic Neurons in Mouse Cerebral Cortex. *Neuron* 91, 1228–1243.

Hirsch, M.-R., d'AuTréaux, F., Dymecki, S.M., Brunet, J.-F., and Goriadis, C. (2013). A *Phox2b:FLPo* transgenic mouse line suitable for intersectional genetics. *Genesis* 51, 506–514.

Hordeaux, J., Wang, Q., Katz, N., Buza, E.L., Bell, P., and Wilson, J.M. (2018). The Neurotropic Properties of AAV-PHP.B Are Limited to C57BL/6J Mice. *Mol. Ther.* 26, 664–668.

Hunter, N.L., Awatramani, R.B., Farley, F.W., and Dymecki, S.M. (2005). Ligand-activated Flpe for temporally regulated gene modifications. *Genesis* 41, 99–109.

Imayoshi, I., Hirano, K., Sakamoto, M., Miyoshi, G., Imura, T., Kitano, S., Miyachi, H., and Kageyama, R. (2012). A multifunctional teal-fluorescent Rosa26 reporter mouse line for Cre- and Flp-mediated recombination. *Neurosci. Res.* 73, 85–91.

Inoue, M., Takeuchi, A., Manita, S., Horigane, S.I., Sakamoto, M., Kawakami, R., Yamaguchi, K., Otomo, K., Yokoyama, H., Kim, R., et al. (2019). Rational Engineering of XCaMPs, a Multicolor GECI Suite for In Vivo Imaging of Complex Brain Circuit Dynamics. *Cell* 177, 1346–1360.e24.

Jensen, P., Farago, A.F., Awatramani, R.B., Scott, M.M., Deneris, E.S., and Dymecki, S.M. (2008). Redefining the serotonergic system by genetic lineage. *Nat. Neurosci.* 11, 417–419.

Jinno, S. (2009). Structural organization of long-range GABAergic projection system of the hippocampus. *Front. Neuroanat.* 3, 13.

Kanki, H., Suzuki, H., and Itohara, S. (2006). High-efficiency CAG-FLPe deleter mice in C57BL/6J background. *Exp. Anim.* 55, 137–141.

Karimova, M., Splith, V., Karpinski, J., Pisabarro, M.T., and Buchholz, F. (2016). Discovery of Nigri/lox and Panto/pox site-specific recombinase systems facilitates advanced genome engineering. *Sci. Rep.* 6, 30130.

Karimova, M., Baker, O., Camgoz, A., Naumann, R., Buchholz, F., and Anastasiadis, K. (2018). A single reporter mouse line for Vika, Flp, Dre, and Cre-recombination. *Sci. Rep.* 8, 14453.

Katayama, H., Yamamoto, A., Mizushima, N., Yoshimori, T., and Miyawaki, A. (2008). GFP-like proteins stably accumulate in lysosomes. *Cell Struct. Funct.* 33, 1–12.

Kato, H.E., Kim, Y.S., Paggi, J.M., Evans, K.E., Allen, W.E., Richardson, C., Inoue, K., Ito, S., Ramakrishnan, C., Fenno, L.E., et al. (2018). Structural mechanisms of selectivity and gating in anion channelrhodopsins. *Nature* 561, 349–354.

Klein, R.L., Dayton, R.D., Leidenheimer, N.J., Jansen, K., Golde, T.E., and Zweig, R.M. (2006). Efficient neuronal gene transfer with AAV8 leads to neurotoxic levels of tau or green fluorescent proteins. *Mol. Ther.* 13, 517–527.

- Kouyama, T., Kanada, S., Takeguchi, Y., Narusawa, A., Murakami, M., and Ihara, K. (2010). Crystal structure of the light-driven chloride pump halorhodopsin from *Natronomonas pharaonis*. *J. Mol. Biol.* 396, 564–579.
- Lao, Z., Raju, G.P., Bai, C.B., and Joyner, A.L. (2012). MASTR: a technique for mosaic mutant analysis with spatial and temporal control of recombination using conditional floxed alleles in mice. *Cell Rep.* 2, 386–396.
- Lazaridis, I., Tzortzi, O., Weglage, M., Martin, A., Xuan, Y., Parent, M., Johansson, Y., Fuzik, J., Fürth, D., Feno, L.E., et al. (2019). A hypothalamus-habenula circuit controls aversion. *Mol. Psychiatry* 24, 1351–1368.
- Lüönd, F., Bill, R., Vettiger, A., Oller, H., Pelczar, P., and Christofori, G. (2019). A Transgenic MMTV-Flippase Mouse Line for Molecular Engineering in Mammary Gland and Breast Cancer Mouse Models. *J. Mammary Gland Biol. Neoplasia* 24, 39–45.
- Madisen, L., Zwingman, T.A., Sunken, S.M., Oh, S.W., Zariwala, H.A., Gu, H., Ng, L.L., Palmiter, R.D., Hawrylycz, M.J., Jones, A.R., et al. (2010). A robust and high-throughput Cre reporting and characterization system for the whole mouse brain. *Nat. Neurosci.* 13, 133–140.
- Madisen, L., Garner, A.R., Shimaoka, D., Chuong, A.S., Klapoetke, N.C., Li, L., van der Bourg, A., Niino, Y., Egolf, L., Monetti, C., et al. (2015). Transgenic mice for intersectional targeting of neural sensors and effectors with high specificity and performance. *Neuron* 85, 942–958.
- Marcinkiewicz, C.A., Mazzone, C.M., D'Agostino, G., Halladay, L.R., Hardaway, J.A., DiBerto, J.F., Navarro, M., Burnham, N., Cristiano, C., Dorrier, C.E., et al. (2016). Serotonin engages an anxiety and fear-promoting circuit in the extended amygdala. *Nature* 537, 97–101.
- Matho, K.S., Huilgol, D., Galbavy, W., Kim, G., He, M., An, X., Lu, J., Wu, P., Di Bella, D.J., Shetty, A.S., Palaniswamy, R., Hatfield, J., Raudales, R., Narasimhan, A., Gamache, E., Levine, J., Tucciarone, J., Mitra, P.P., Osten, P., Ariotta, P., and Huang, Z.J. (2020). Genetic dissection of glutamatergic neuron subpopulations and developmental trajectories in the cerebral cortex. *bioRxiv*. <https://doi.org/10.1101/2020.04.22.054064>.
- Mingote, S., Amsellem, A., Kempf, A., Rayport, S., and Chuhma, N. (2019). Dopamine-glutamate neuron projections to the nucleus accumbens medial shell and behavioral switching. *Neurochem. Int.* 129, 104482.
- Miyoshi, G., Hjerling-Leffler, J., Karayannis, T., Sousa, V.H., Butt, S.J.B., Battiste, J., Johnson, J.E., Machold, R.P., and Fishell, G. (2010). Genetic fate mapping reveals that the caudal ganglionic eminence produces a large and diverse population of superficial cortical interneurons. *J. Neurosci.* 30, 1582–1594.
- Nakano, M., Ishimura, M., Chiba, J., Kanegae, Y., and Saito, I. (2001). DNA substrates influence the recombination efficiency mediated by FLP recombinase expressed in mammalian cells. *Microbiol. Immunol.* 45, 657–665.
- Nathanson, J.L., Yanagawa, Y., Obata, K., and Callaway, E.M. (2009). Preferential labeling of inhibitory and excitatory cortical neurons by endogenous tropism of adeno-associated virus and lentivirus vectors. *Neuroscience* 161, 441–450.
- Petropoulos, S., Edsgård, D., Reinius, B., Deng, Q., Panula, S.P., Codeluppi, S., Plaza Reyes, A., Linnarsson, S., Sandberg, R., and Lanner, F. (2016). Single-Cell RNA-Seq Reveals Lineage and X Chromosome Dynamics in Human Preimplantation Embryos. *Cell* 165, 1012–1026.
- Piccirillo, R., Palmisano, I., Innamorati, G., Bagnato, P., Altmare, D., and Schiaffino, M.V. (2006). An unconventional dileucine-based motif and a novel cytosolic motif are required for the lysosomal and melanosomal targeting of OA1. *J. Cell Sci.* 119, 2003–2014.
- Platt, R.J., Chen, S., Zhou, Y., Yim, M.J., Swiech, L., Kempton, H.R., Dahlman, J.E., Parnas, O., Eisenhaure, T.M., Jovanovic, M., et al. (2014). CRISPR-Cas9 knockin mice for genome editing and cancer modeling. *Cell* 159, 440–455.
- Plummer, N.W., Evsyukova, I.Y., Robertson, S.D., de Marchena, J., Tucker, C.J., and Jensen, P. (2015). Expanding the power of recombination-based labeling to uncover cellular diversity. *Development* 142, 4385–4393.
- Poulin, J.F., Caronia, G., Hofer, C., Cui, Q., Helm, B., Ramakrishnan, C., Chan, C.S., Dombeck, D.A., Deisseroth, K., and Awatramani, R. (2018). Mapping projections of molecularly defined dopamine neuron subtypes using intersectional genetic approaches. *Nat. Neurosci.* 21, 1260–1271.
- Raymond, C.S., and Soriano, P. (2007). High-efficiency FLP and PhiC31 site-specific recombination in mammalian cells. *PLoS ONE* 2, e162.
- Reimsnider, S., Manfredsson, F.P., Muzyczka, N., and Mandel, R.J. (2007). Time course of transgene expression after intrastriatal pseudotyped rAAV2/1, rAAV2/2, rAAV2/5, and rAAV2/8 transduction in the rat. *Mol. Ther.* 15, 1504–1511.
- Ringrose, L., Lounnas, V., Ehrlich, L., Buchholz, F., Wade, R., and Stewart, A.F. (1998). Comparative kinetic analysis of FLP and cre recombinases: mathematical models for DNA binding and recombination. *J. Mol. Biol.* 284, 363–384.
- Robertson, S.D., Plummer, N.W., de Marchena, J., and Jensen, P. (2013). Developmental origins of central norepinephrine neuron diversity. *Nat. Neurosci.* 16, 1016–1023.
- Rodríguez, C.I., Buchholz, F., Galloway, J., Sequerra, R., Kasper, J., Ayala, R., Stewart, A.F., and Dymecki, S.M. (2000). High-efficiency deleter mice show that FLP is an alternative to Cre-loxP. *Nat. Genet.* 25, 139–140.
- Satija, R., Farrell, J.A., Gennert, D., Schier, A.F., and Regev, A. (2015). Spatial reconstruction of single-cell gene expression data. *Nat. Biotechnol.* 33, 495–502.
- Schlake, T., and Bode, J. (1994). Use of mutated FLP recognition target (FRT) sites for the exchange of expression cassettes at defined chromosomal loci. *Biochemistry* 33, 12746–12751.
- Schönhuber, N., Seidler, B., Schuck, K., Veltkamp, C., Schachtler, C., Zukowska, M., Eser, S., Feyerabend, T.B., Paul, M.C., Eser, P., et al. (2014). A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer. *Nat. Med.* 20, 1340–1347.
- Schuman, B., Machold, R.P., Hashikawa, Y., Fuzik, J., Fishell, G.J., and Rudy, B. (2019). Four unique interneuron populations reside in neocortical layer 1. *J. Neurosci.* 39, 125–139.
- Sohal, V.S., Zhang, F., Yizhar, O., and Deisseroth, K. (2009). Parvalbumin neurons and gamma rhythms enhance cortical circuit performance. *Nature* 459, 698–702.
- Sun, J.J., and Ray, R. (2016). Generation of Two Noradrenergic-Specific Dopamine-Beta-Hydroxylase-FLPo Knock-In Mice Using CRISPR/Cas9-Mediated Targeting in Embryonic Stem Cells. *PLoS ONE* 11, e0159474.
- Suzuki, E., and Nakayama, M. (2011). VCre/VloxP and SCre/SloxP: new site-specific recombination systems for genome engineering. *Nucleic Acids Res.* 39, e49.
- Takeuchi, T., Nomura, T., Tsujita, M., Suzuki, M., Fuse, T., Mori, H., and Mishina, M. (2002). Flp recombinase transgenic mice of C57BL/6 strain for conditional gene targeting. *Biochem. Biophys. Res. Commun.* 293, 953–957.
- Tervo, D.G.R., Hwang, B.Y., Viswanathan, S., Gaj, T., Lavzin, M., Ritola, K.D., Lindo, S., Michael, S., Kuleshova, E., Ojala, D., et al. (2016). A Designer AAV Variant Permits Efficient Retrograde Access to Projection Neurons. *Neuron* 92, 372–382.
- Ting, J.T., Daigle, T.L., Chen, Q., and Feng, G. (2014). Acute Brain Slice Methods for Adult and Aging Animals: Application of Targeted Patch Clamp Analysis and Optogenetics (Humana Press), pp. 221–242.
- Tovote, P., Esposito, M.S., Botta, P., Chaudun, F., Fadok, J.P., Markovic, M., Wolff, S.B., Ramakrishnan, C., Feno, L., Deisseroth, K., et al. (2016). Midbrain circuits for defensive behaviour. *Nature* 534, 206–212.
- Ventura, A., Meissner, A., Dillon, C.P., McManus, M., Sharp, P.A., Van Parijs, L., Jaenisch, R., and Jacks, T. (2004). Cre-lox-regulated conditional RNA interference from transgenes. *Proc. Natl. Acad. Sci. USA* 101, 10380–10385.
- Villette, V., Chavarha, M., Dimov, I.K., Bradley, J., Pradhan, L., Mathieu, B., Evans, S.W., Chamberland, S., Shi, D., Yang, R., et al. (2019). Ultrafast Two-Photon Imaging of a High-Gain Voltage Indicator in Awake Behaving Mice. *Cell* 179, 1590–1608.e23.
- Vooijs, M., van der Valk, M., te Riele, H., and Berns, A. (1998). Flp-mediated tissue-specific inactivation of the retinoblastoma tumor suppressor gene in the mouse. *Oncogene* 17, 1–12.

- Vrontou, S., Wong, A.M., Rau, K.K., Koerber, H.R., and Anderson, D.J. (2013). Genetic identification of C fibres that detect massage-like stroking of hairy skin in vivo. *Nature* 493, 669–673.
- Wang, X., Allen, W.E., Wright, M.A., Sylwestrak, E.L., Samusik, N., Vesuna, S., Evans, K., Liu, C., Ramakrishnan, C., Liu, J., et al. (2018). Three-dimensional intact-tissue sequencing of single-cell transcriptional states. *Science* 361, eaat5691.
- Weinberg, B.H., Pham, N.T.H., Caraballo, L.D., Lozano, T., Engel, A., Bhatia, S., and Wong, W.W. (2017). Large-scale design of robust genetic circuits with multiple inputs and outputs for mammalian cells. *Nat. Biotechnol.* 35, 453–462.
- Wojcinski, A., Morabito, M., Lawton, A.K., Stephen, D.N., and Joyner, A.L. (2019). Genetic deletion of genes in the cerebellar rhombic lip lineage can stimulate compensation through adaptive reprogramming of ventricular zone-derived progenitors. *Neural Dev.* 14, 4.
- Wu, Y., Wang, C., Sun, H., LeRoith, D., and Yakar, S. (2009). High-efficient FLPO deleter mice in C57BL/6J background. *PLoS ONE* 4, e8054.
- Wu, J., Liu, X., Nayak, S.G., Pitarresi, J.R., Cuitiño, M.C., Yu, L., Hildreth, B.E., 3rd, Thies, K.A., Schilling, D.J., Fernandez, S.A., et al. (2017). Generation of a pancreatic cancer model using a Pdx1-Flp recombinase knock-in allele. *PLoS ONE* 12, e0184984.
- Yizhar, O., Fenno, L.E., Davidson, T.J., Mogri, M., and Deisseroth, K. (2011). Optogenetics in neural systems. *Neuron* 71, 9–34.
- Yu, J., and McMahon, A.P. (2006). Reproducible and inducible knockdown of gene expression in mice. *Genesis* 44, 252–261.
- Yu, K., Ahrens, S., Zhang, X., Schiff, H., Ramakrishnan, C., Fenno, L., Deisseroth, K., Zhao, F., Luo, M.H., Gong, L., et al. (2017). The central amygdala controls learning in the lateral amygdala. *Nat. Neurosci.* 20, 1680–1685.
- Yu, J.Y., Pettibone, J.R., Guo, C., Zhang, S., Saunders, T.L., Hughes, E.D., Filipiak, W.E., Zeidler, M.G., Bender, K.J., Hopf, F., et al. (2018). Knock-in rats expressing Cre and Flp recombinases at the Parvalbumin locus. *BioRxiv*. <https://doi.org/10.1101/386474>.
- Zhang, F. (2008). Larry M. Katz Memorial Lecture, Cold Spring Harbor Laboratory Meeting on Neuronal Circuits (Cold Spring Harbor Laboratory, March 2008).
- Zhang, M.D., Su, J., Adori, C., Cinquina, V., Malenczyk, K., Girach, F., Peng, C., Ernfor, P., Löw, P., Borgius, L., et al. (2018). Ca²⁺-binding protein NECAB2 facilitates inflammatory pain hypersensitivity. *J. Clin. Invest.* 128, 3757–3768.

STAR★METHODS

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Bacterial and Virus Strains		
One Shot Stbl3 <i>e-coli</i>	ThermoFisher	Cat# C737303
Adeno-Associated Virus Coat Protein 2/8	Stanford GVVC	AAV8
Adeno-Associated Virus Coat Protein 2/retro	Stanford GVVC	AAV-retro
pAAV-EF1a-FlpO-p2a-Cre	This Paper	Stanford GVVC AAV8
pAAV-EF1a-FlpO	Fenno et al., 2014	Stanford GVVC AAV8
pAAV-EF1a-FlpO	Fenno et al., 2014	Stanford GVVC AAV-retro
pAAV-EF1a-Cre	Fenno et al., 2014	Stanford GVVC AAV8
pAAV-EF1a-VCre	Fenno et al., 2014	Stanford GVVC AAV8
pAAV-EF1a-VCre	Fenno et al., 2014	Stanford GVVC AAV-retro
pAAV-cDIO-EYFP	Fenno et al., 2014	Stanford GVVC AAV8
pAAV-fDIO-EYFP	Fenno et al., 2014	Stanford GVVC AAV8
pAAV-vcDIO-EYFP	Fenno et al., 2014	Stanford GVVC AAV8
pAAV-Ef1a-EYFP	This paper	Stanford GVVC AAV8
pAAV-Ef1a-Con/Fon-EYFP	Fenno et al., 2014	Stanford GVVC AAV8
pAAV-Ef1a-Con/Foff-EYFP	Fenno et al., 2014	Stanford GVVC AAV8
pAAV-Ef1a-Coff/Fon-EYFP	Fenno et al., 2014	Stanford GVVC AAV8
pAAV-Ef1a-Con/Foff 2.0-EYFP	This Paper	Stanford GVVC AAV8
pAAV-nEF-3x-EYFP	This Paper	Addgene Cat# 137163
pAAV-Ef1a-3x-GCaMP6M	This Paper	Addgene Cat# 137164
Chemicals, Peptides, and Recombinant Proteins		
AP-V	Tocris	Cat# 0106
CNQX	Tocris	Cat# 0190
Fluorodeoxyuridine (FUDR)	Sigma	Cat# F0503
Lipofectamine 2000	ThermoFisher	Cat# 11668027
Propidium Iodide	Sigma	Cat# P4170
RNeasy Mini Kit	QIAGEN	Cat # 74106
SuperScript III One-Step RT-PCR System	ThermoFisher	Cat # 12574026
Tetrodotoxin	Tocris	Cat #1078
Experimental Models: Cell Lines		
Rat Hippocampal Primary Neurons	Derived In-House	N/A
HEK293 Cells	ThermoFisher Scientific	Cat # R70007
Experimental Models: Organisms/Strains		
WT C57/BL6 mice	Jackson Laboratories	Cat# 000664
SST-Cre C57/BL6 transgenic mice	Jackson Laboratories	Cat# 013044
TH-Cre C57/BL6 transgenic mice	EMMA	Cat# 00254
Sprague-Dawley rat pups	Charles River	n/a
Oligonucleotides		
See Table S1	N/A	N/A
Recombinant DNA		
pAAV-EF1a-Con/Fon-GCaMP6M	This Paper	Addgene Cat# 137119
pAAV-Ef1a-Con/Foff-GCaMP6M	This Paper	N/A
pAAV-Ef1a-Con/Foff 2.0-GCaMP6M	This Paper	Addgene Cat# 137120
pAAV-Ef1a-Coff/Fon-GCaMP6M	This Paper	Addgene Cat# 137121

(Continued on next page)

Continued

REAGENT or RESOURCE	SOURCE	IDENTIFIER
pAAV-Ef1a-Con/Fon-GCaMP6F	This Paper	Addgene Cat# 137122
pAAV-Ef1a-Con/Foff-GCaMP6F	This Paper	N/A
pAAV-Ef1a-Con/Foff 2.0-GCaMP6F	This Paper	Addgene Cat# 137123
pAAV-Ef1a-Coff/Fon-GCaMP6F	This Paper	Addgene Cat# 137124
pAAV-Ef1a-sRGECO	This Paper	Addgene Cat# 137125
pAAV-Ef1a-Con/Fon-sRGECO	This Paper	Addgene Cat# 137126
pAAV-Ef1a-Con/Foff-sRGECO	This Paper	N/A
pAAV-Ef1a-Con/Foff 2.0-sRGECO	This Paper	Addgene Cat# 137127
pAAV-Ef1a-Coff/Fon-sRGECO	This Paper	Addgene Cat# 137128
pAAV-Ef1a-Con/Fon-BFP	This Paper	Addgene Cat# 137129
pAAV-Ef1a-Con/Foff-BFP	This Paper	N/A
pAAV-Ef1a-Con/Foff 2.0-BFP	This Paper	Addgene Cat# 137130
pAAV-Ef1a-Coff/Fon-BFP	This Paper	Addgene Cat# 137131
pAAV-Ef1a-Con/Fon-mCherry	This Paper	Addgene Cat# 137132
pAAV-Ef1a-Con/Foff-mCherry	This Paper	N/A
pAAV-Ef1a-Con/Foff 2.0-mCherry	This Paper	Addgene Cat# 137133
pAAV-Ef1a-Coff/Fon-mCherry	This Paper	Addgene Cat# 137134
pAAV-Ef1a-oScarlet	This Paper	Addgene Cat# 137135
pAAV-Ef1a-Con/Fon-oScarlet	This Paper	Addgene Cat# 137136
pAAV-Ef1a-Con/Foff-oScarlet	This Paper	N/A
pAAV-Ef1a-Con/Foff 2.0-oScarlet	This Paper	Addgene Cat# 137137
pAAV-Ef1a-Coff/Fon-oScarlet	This Paper	Addgene Cat# 137138
pAAV-nEF-Con/Fon-ChR2(ET/TC)-EYFP	This Paper	Addgene Cat# 137139
pAAV-nEF-Con/Foff-ChR2(ET/TC)-EYFP	This Paper	N/A
pAAV-nEF-Con/Foff 2.0-ChR2(ET/TC)-EYFP	This Paper	Addgene Cat# 137140
pAAV-nEF-Coff/Fon-ChR2(ET/TC)-EYFP	This Paper	Addgene Cat# 137141
pAAV-nEF-Con/Fon-ChR2-mCherry	This Paper	Addgene Cat# 137142
pAAV-nEF-Con/Foff-ChR2-mCherry	This Paper	N/A
pAAV-nEF-Con/Foff 2.0-ChR2-mCherry	This Paper	Addgene Cat# 137143
pAAV-nEF-Coff/Fon-ChR2-mCherry	This Paper	Addgene Cat# 137144
pAAV-nEF-Con/Fon-bREACHes-EYFP	This Paper	Addgene Cat# 137145
pAAV-nEF-Con/Foff-bREACHes-EYFP	This Paper	N/A
pAAV-nEF-Con/Foff 2.0-bREACHes-EYFP	This Paper	Addgene Cat# 137146
pAAV-nEF-Coff/Fon-bREACHes-EYFP	This Paper	Addgene Cat# 137147
pAAV-nEF-Con/Fon-Arch 3.3-p2a-EYFP	This Paper	Addgene Cat# 137148
pAAV-nEF-Con/Foff-Arch 3.3-EYFP	This Paper	N/A
pAAV-nEF-Con/Foff 2.0-Arch 3.3-EYFP	This Paper	Addgene Cat# 137149
pAAV-nEF-Coff/Fon-Arch 3.3-p2a-EYFP	This Paper	Addgene Cat# 137150
pAAV-nEF-NpHR3.3-EYFP	This Paper	Addgene Cat# 137151
pAAV-nEF-Con/Fon-NpHR 3.3-EYFP	This Paper	Addgene Cat# 137152
pAAV-nEF-Con/Foff-NpHR 3.3-EYFP	This Paper	N/A
pAAV-nEF-Con/Foff 2.0-NpHR 3.3-EYFP	This Paper	Addgene Cat# 137153
pAAV-nEF-Coff/Fon-NpHR 3.3-EYFP	This Paper	Addgene Cat# 137154
pAAV-nEF-Con/Fon-iC++-EYFP	This Paper	Addgene Cat# 137155
pAAV-nEF-Con/Foff-iC++-EYFP	This Paper	N/A
pAAV-nEF-Con/Foff 2.0-iC++-EYFP	This Paper	Addgene Cat# 137156
pAAV-nEF-Coff/Fon-iC++-EYFP	This Paper	Addgene Cat# 137157
pAAV-nEF-ChRmine-mScarlet	This Paper	Addgene Cat# 137158

(Continued on next page)

Continued

REAGENT or RESOURCE	SOURCE	IDENTIFIER
pAAV-nEF-Con/Fon-ChRmine 3.3-oScarlet	This Paper	Addgene Cat# 137159
pAAV-nEF-Coff/Fon-ChRmine 3.3-oScarlet	This Paper	Addgene Cat# 137160
pAAV-nEF-Con/Foff-ChRmine 3.3-oScarlet	This Paper	N/A
pAAV-nEF-Con/Foff 2.0-ChRmine 3.3-oScarlet	This Paper	Addgene Cat# 137161
pAAV-Ef1a-Con/Foff 2.0-EYFP	This Paper	Addgene Cat# 137162
pAAV-nEF-Con/Foff 2.0-ChR2-EYFP	This Paper	Addgene Cat# 137163
pAAV-nEF-3x-EYFP	This Paper	Addgene Cat# 137164
pAAV-Ef1a-3x-GCaMP6M	This Paper	Addgene Cat# 137165
Software and Algorithms		
ImageJ	NIH	https://imagej.nih.gov/ij/
SnapGene	GSL Biotech LLC	https://www.snapgene.com:443/
FlowJo	Flowjo	https://www.flowjo.com
Pymol	Schrodinger	https://www.pymol.org/2/
Netgene2 splicing algorithm	DTU Bioinformatics	http://www.cbs.dtu.dk/services/NetGene2/
MATLAB	MathWorks	https://www.mathworks.com/products/matlab.html
Metamorph	Molecular Devices	https://www.moleculardevices.com
pClamp 10.6	Molecular Devices	https://www.moleculardevices.com
CueMol: Molecular Visualization Framework	Cuemol	http://www.cuemol.org/
Other		
MultiClamp700B Amplifier	Molecular Devices	https://www.moleculardevices.com
DigiData 1440A	Molecular Devices	https://www.moleculardevices.com
DM-LFSA	Leica	N/A
Power meter	Thorlabs	PM100D
200 um implants	Doric	MFC_200/245-0.53_3.5mm_MF2.5_FLT
400 um implants	Doric	MFC_400/430-0.66_15mm_MF2.5_FLT (cut to length)
DxP FACSCAN	Becton Dickinson	https://www.bdbiosciences.com/en-us
SPECTRA-X Light Engine	Lumencor	https://lumencor.com
3D-printed well insert	This Paper	https://www.protolabs.com
Compact CCD Spectrometer	Thorlabs	CCS100
Fiber Bundle	Thorlabs	BFL200LS02
Reflective Collimator	Thorlabs	RC04SMA-P01
Zoom Lens Tube	Thorlabs	SM1NR05
Lens	Edmund Optics	#62-561
Filter Holder	Thorlabs	CFH2
Lens Tube Coupler	Thorlabs	Sm1T20
Kinematic Dichroic Filter Mount, 30mm	Thorlabs	DFM1
End Cap	Thorlabs	SM1CP2
Sm1 Threaded Adaptor	Thorlabs	AD12F
Fixed Focus Collimator	Thorlabs	F240FC-A
SM1 coupler	Thorlabs	SM1NT
Multimode Fiber Optic Patch Cable (FCPC to SMA)	Thorlabs	m76L01
LED Controller	Thorlabs	LEDD1B
Fiber-Coupled LED	Thorlabs	M505F1
Excitation Bandpass Filter	Thorlabs	MF497-16
Dichroic	Chroma	T525LPXR
Emission Bandpass Filter	Thorlabs	MF535-22

RESOURCE AVAILABILITY

Lead Contact

All reagents detailed in this manuscript are freely available for academic use from the Deisseroth Lab (http://www.stanford.edu/group/dlab/optogenetics/sequence_info.html) and via the Lead Contact (Karl Deisseroth; deissero@stanford.edu).

Materials Availability

Most plasmids and viruses are also available through AddGene (<http://www.addgene.org/>; see [Key Resources Table](#)) and/or the Stanford Viral Vector Core (<https://neuroscience.stanford.edu/research/programs/community-labs/neuroscience-gene-vector-and-virus-core>). The Flp mouse line database is maintained by the Deisseroth Lab (http://www.stanford.edu/group/dlab/optogenetics/flip_lines.html). A standard operating procedure for INTRSECT reagents is also available (https://web.stanford.edu/group/dlab/optogenetics/intrsect_sop.pdf).

Data and Code Availability

No stand-alone code was generated for this project, however, MATLAB code available upon request from lead contact.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Animals

Adult (at least 8 weeks of age) wild-type female and transgenic Sst^{tm(Cre)} (somatostatin-IRES-Cre; Jax 013044; RRID:IMSR_JAX:013044) mice were group housed up to four to a cage and kept on a reverse 12-h light/dark cycle with *ad libitum* food and water. Experimental protocols were approved by and conform to Stanford University IACUC and meet guidelines of the US National Institutes of Health guide for the Care and Use of Laboratory Animals. See [Key Resources Table](#) for specific transgenic animal strain information.

Flp Line Database

To locate transgenic, Flp-expressing mouse lines, the following websites were searched using the term ‘Flp’ (with the exception of Google Scholar, where the term ‘Flp driver mouse line’ was used) in September, 2018 and November, 2019, and the results were manually assessed.

Jackson Labs	https://www.jax.org/mouse-search
MMRRC	https://www.mmrrc.org/catalog/StrainCatalogSearchForm.php
APF	https://pb.apf.edu.au/phenbank/findstrains.html
NIH Blueprint	http://www.credrivermice.org/
GENSAT	http://www.gensat.org/cre.jsp
Taconic	https://www.taconic.com/find-your-model/
Mousebook	https://www.mousebook.org/
MGI	http://www.informatics.jax.org/downloads/reports/MGI_Recombinase_Full.html
RIKEN	https://mus.list.brc.riken.jp/en/
RRRC	http://www.rrrc.us/
Google	https://scholar.google.com/
Pubmed	https://pubmed.ncbi.nlm.nih.gov/

The initial publications describing the production of the lines were assessed for the construction method, promoter, and Flp variant. In cases where animals located in publications were not found in available repositories or when animal lines in repositories were not found in publications, the corresponding author or listed depositor was directly contacted for more information and for direction in how other researchers can acquire the lines.

Primary Neuronal Cell Cultures

Primary cultured hippocampal neurons were prepared from P0 Sprague-Dawley rat pups (Charles River). CA1 and CA3 from entire litters (male and female pups) were isolated, digested with 0.4 mg ml⁻¹ papain (Worthington), and plated onto glass coverslips

precoated with 1:30 Matrigel (Becton Dickinson Labware). Cultures were maintained in a 5% CO₂ humid incubator with Neurobasal-A media (Thermo Fisher) containing 1.25% FBS (HyClone), 4% B-27 supplement (GIBCO), 2 mM Glutamax (GIBCO) and 2 mg/ml fluoro-deoxyuridine (FUDR, Sigma), and grown on coverslips in a 24-well plate at a density of 65,000 cells per well.

HEK293 Cell Cultures

HEK293FT cells (Thermo Fisher) were maintained in a 5% CO₂ humid incubator with DMEM media (GIBCO) supplemented with 10% FBS (Invitrogen), 1% Glutamax (Invitrogen), and 1x Penicillin-Streptomycin (Invitrogen). They were enzymatically passaged at 90% confluence by trypsinization.

METHOD DETAILS

Molecular cloning

All single recombinase-dependent plasmids were constructed in an AAV-Ef1 α backbone using the double-floxed inverted open-reading-frame (DIO) strategy described previously (Atasoy et al., 2008; Sohal et al., 2009); briefly, the ORF is in the reverse complement orientation between two cassettes of recombinase recognition sites. See the [Key Resources Table](#) for information specific to the Cre-dependent (cDIO), Flp-dependent (fDIO) vCre-dependent (vcDIO), Dre-dependent (dDIO), and sCre-dependent (scDIO) iterations. dDIO rox cassette was previously described (Fenno et al., 2014). This, and all constructs used in this paper, contain the wood-chuck hepatitis virus post-transcriptional regulatory element (WPRE) to enhance expression.

A series of recombinase-expression plasmids were used, as detailed in the [Key Resources Table](#). All recombinase expression plasmids were constructed in an AAV-EF1 α backbone. These were made as fluorophore-expressing, bicistronic plasmids (using an internal ribosomal entry site or p2a sequence), or without any visual marker, as indicated in the text and figures. FlpO (Raymond and Soriano, 2007) was used for Flp-dependent expression.

Mutations to NpHR, jRGECO1a, and mScarlett were introduced via overlapping PCR with primers containing the mutation. The NpHR W179F mutation was chosen from amino acids more than 8 Å away from the retinal binding pocket / ion-pumping pathway by analyzing the crystal structure of NpHR (PDB ID: 3A7K; Kouyama et al., 2010). The jRGECO1a (Dana et al., 2016) mutation E217D and the mScarlett (Bindels et al., 2017) mutation E95D was chosen to improve functional expression by interrupting a lysosomal import motif (Piccirillo et al., 2006). jRGECO1a, sRGECO, mScarlett, and oScarlett inclusion quantification was performed by viral infection (jRGECO1a and sRGECO) or calcium-phosphate transfection (mScarlett and oScarlett) of primary neuron cultures, followed by 4% PFA fixation, mounting, imaging on a confocal, and blinded manual analysis with randomly shuffled and anonymized image labeling.

Tools noted to be '3.3' versions (NpHR, ChRmine, and Arch) include the addition of endoplasmic reticulum and membrane trafficking motifs previously described (Gradinaru et al., 2010), as well as the addition of a p2a bicistronic expression sequence that allows for independent translation of opsin and fluorophore from a single mRNA transcript.

INTRSECT constructs were produced with either one intron (for single ORF, two-recombinase-dependent tools), two introns (for double ORF, two-recombinase-dependent tools), or two introns (for single ORF, three-recombinase-dependent tools).

Single ORF, two-recombinase-dependent INTRSECT plasmids were constructed by splitting the reading frame into two pieces (referred to as 'exon 1' and 'exon 2') after being analyzed for naturally occurring splice-site-like sequences using a public bioinformatics tool (<http://www.cbs.dtu.dk/services/NetGene2/>; Brunak et al., 1991), designed as possible to have the splice site disrupt the reading frame to decrease the chance of partial protein synthesis from exon 2 in the absence of the pre-defined expression criteria. A derivative of the mouse IgE intron 3 (Fenno et al., 2014) containing a cDIO cassette and fDIO cassette was inserted between the exons, with the donor and acceptor sites fused directly to the 3' terminus of exon 1 and 5' terminus of exon 2, respectively. A separate cDIO cassette was added directly after the promoter (5' to the entire coding sequence) and a fDIO cassette was added directly before the WPRE (3' to the entire coding sequence). To create Con/Fon constructs, both exons are in the reverse complement orientation. To create Con/Foff constructs, exon 1 is in the reverse complement orientation and exon 2 is in the sense direction. To create Coff/Fon constructs, exon 1 is in the sense direction and exon 2 is in the reverse complement orientation. All of these plasmids are constructed in an AAV-EF1 α backbone with a 3' WPRE and are detailed in the [Key Resources Table](#).

Double ORF, two-recombinase-dependent INTRSECT plasmids were constructed by splitting the reading frame into three pieces (referred to as 'exon 1', 'exon 2', and 'exon 3') after being analyzed for naturally occurring splice-site-like sequences using a public bioinformatics tool (<http://www.cbs.dtu.dk/services/NetGene2/>; Brunak et al., 1991) and choosing a splice site in each of the reading frames, designed as possible to have the splice sites disrupt the reading frame to decrease the chance of partial protein synthesis from exon 2 or exon 3 in the absence of the pre-defined expression criteria. A derivative of the CMV Towne Variant intron B (Fenno et al., 2014) containing a cDIO cassette was inserted between exon 1 and exon 2, with the donor and acceptor sites fused directly to the 3' terminus of exon 1 and 5' terminus of exon 2, respectively. A derivative of the mouse IgE intron 3 (Fenno et al., 2014) containing a cDIO cassette was inserted between exon 2 and exon 3, with the donor and acceptor sites fused directly to the 3' terminus of exon 2 and 5' terminus of exon 3, respectively. Separate fDIO cassettes were added directly after the promoter (5' to the entire coding sequence) and directly before the WPRE (3' to the entire coding sequence). To create Con/Fon constructs, the exon order is exon 3, exon 2, exon 1, with exons 1 and 3 in the reverse complement orientation and exon 2 in the sense orientation. To create Con/Foff constructs, the exon order is exon 1, exon 2, exon 3, with exons 1 and 3 in the sense orientation and exon 2 in the reverse

complement orientation. To create Coff/Fon constructs, the exon order is exon 3, exon 2, exon 1, with all exons in the reverse complement orientation. All of these plasmids are constructed in an AAV-nEF backbone with a 3' WPRE and are detailed in the [Key Resources Table](#).

Single ORF, three-recombinase-dependent INTRSECT plasmids were constructed by splitting the reading frame into three pieces (referred to as 'exon 1', 'exon 2', and 'exon 3') after being analyzed for naturally occurring splice-site-like sequences using a public bioinformatics tool (<http://www.cbs.dtu.dk/services/NetGene2/>; Brunak et al., 1991), designed as possible to have the splice site disrupt the reading frame to decrease the chance of partial protein synthesis from exon 2 or exon 3 in the absence of the pre-defined expression criteria. A derivative of the CMV Towne Variant intron B (Fenno et al., 2014) containing a cDIO cassette and fDIO (F3/F5-based) cassette was inserted between exon 1 and exon 2, with the donor and acceptor sites fused directly to the 3' terminus of exon 1 and 5' terminus of exon 2, respectively. A derivative of the mouse IgE intron 3 (Fenno et al., 2014) containing a fDIO cassette and vcDIO cassette was inserted between exon 2 and exon 3, with the donor and acceptor sites fused directly to the 3' terminus of exon 2 and 5' terminus of exon 3, respectively. A separate cDIO cassette was added directly after the promoter (5' to the entire coding sequence) and a vcDIO cassette was added directly before the WPRE (3' to the entire coding sequence). To create Con/Fon/VCon constructs, the exon order is exon 1, exon 2, exon 3, with all exons in the reverse complement orientation. All of these plasmids are constructed in an AAV-nEF backbone with a 3' WPRE and are detailed in the [Key Resources Table](#).

To produce FRT variants for screening Con/Foff improvements, the FRT, F3, F5 (Schlake and Bode, 1994), and F72 (Nakano et al., 2001) sequences were built into various combinations of AAV-EF1 α -Con/Foff-EYFP. In addition, a 14bp addition noted from the genomic FRT sequence (Andrews et al., 1985) was added either to the 5' or 3' (or both) ends of F3, F5, and/or FRT in configurations. These were synthesized *de novo* and incorporated into the Flp cassette using standard cloning techniques. After screening, the FRT-F5 cassette was incorporated into all Con/Foff constructs.

FRT variant	5' repeat	8bp central motif	3' repeat
FRT	gaagtcctattc	tctagaaa	gtataggaacttc
F3	gaagtcctattc	ttcaaata	gtataggaacttc
F5	gaagtcctattc	ttcaaaag	gtataggaacttc
F72	gaagtcctattc	tgtagaaa	gtataggaacttc
14bp addition	gaagtcctattcc		

All AAV vectors were tested for *in vitro* expression before viral production. Maps are available at <http://www.stanford.edu/group/dlab/optogenetics>.

sRGECO and oScarlet development

Prior to entering mScarlet and jRGECO1a into the INTRSECT production pipeline, we observed fluorescent puncta (assumed to be protein aggregates) when expressed either *in vitro* (mScarlet; [Figure S1B](#)) or *in vivo* (jRGECO1a; [Figure S2B](#)). Both are based on monomeric Red Fluorescent Protein (Bindels et al., 2017; Dana et al., 2016), which is known to be degradation-resistant and accumulate in lysosomes (Katayama et al., 2008). We found that the unconventional lysosomal targeting motif tryptophan-glutamic acid (Piccirillo et al., 2006) was conserved in both of these tools. To overcome this aggregation problem we mutated this motif mScarlet(E95D) ('oScarlet' for 'optimized'; [Figure S1A](#)) and jRGECO1a(E217D) ('sRGECO' for 'Stanford' and 'smooth'; [Figure S2A](#)). oScarlet had significantly fewer aggregates in cultured neurons (25.9 per neuron in mScarlet, 0.58 per neuron in oScarlet, $p < 0.0001$, Mann-Whitney test), with no obvious difference in fluorescence intensity as assayed by flow cytometry ([Figures S1B and S1C](#)). The distribution of aggregates in sRGECO were significantly less relative to jRGECO1a in mouse mPFC ($p = 0.0368$, Kolmogorov-Smirnov test), without a difference in either mean aggregates per neuron or total fluorescence across the imaged cortical slices ([Figures S2B and S2C](#); mean aggregates 6.96 per neuron in jRGECO1a versus 5.73 per neuron in sRGECO, $p = 0.7846$, Mann-Whitney test, total integrated fluorescence $p = 0.1867$, unpaired t test. N as indicated). To characterize this improved GECI more thoroughly, we designed a small, 3D-printable well insert for electrical stimulation of cultured neurons using a 100 mA source applied through platinum wires ([Figure S2D](#)). *In vitro* characterization of sRGECO and jRGECO1a ([Figure S2E](#)) revealed a difference in basal fluorescence and related differences in signal magnitude, but intact function. Considering the improved expression patterns of oScarlet and sRGECO, we used these versions as the sequence base for creating their INTRSECT variants.

mRNA isolation and cDNA synthesis

HEK293FT cells at 50% confluence were transfected with endotoxin-free DNA using Lipofectamine 2000 (Thermo Fisher) following the manufacturer protocol. Five days post transfection, RNA extraction was performed using reagents from the RNeasy Mini Kit (QIAGEN). Cells were disrupted with lysis buffer and homogenized using QiaShredder homogenizer columns. Combined first-strand cDNA/PCR using the SuperScript III One-Step RT-PCR System (Thermo Fisher) was performed with the following initial reaction

conditions: 45°C . 30 min, 94°C . 2 min, 40 cycles of 94°C . 15 s, 45°C . 30 s, 68°C . 1 min, ending with 68°C . 5 min using various combinations of primers (F, forward; R, reverse) as noted in the [Key Resources Table](#) and sometimes optimized further to reduce off-target amplicons. The PCR product was electrophoresed on a 0.8% agarose gel, photographed, and DNA bands purified from the gel and sequenced to determine splice junctions.

Flow cytometry

HEK293FT cells (Thermo Fisher) were grown in 24-well tissue culture plates to 50% confluence and transfected in duplicate with 800 ng total DNA with Lipofectamine 2000 (Thermo Fisher) following the manufacturer protocol. In dual-recombinase INTRASECT plasmid experiments, 267ng of each plasmid was used, except in recombinase ratio experiments, where a fixed amount of INTRASECT plasmid and variable ratios of Cre and Flp, as noted in the figure, were added. In Triplesect experiments, 200ng of each plasmid was added. Five days post transfection, cells were removed by enzymatic dissociation (TrypLE, GIBCO), resuspended in cold PBS, pelleted at 200g for 5 min and resuspended in 500 μ L PBS supplemented with 1 μ g/mL propidium iodide (PI; Sigma, used with green and blue fluorescent constructs) or 5 μ M 4'6-diamidino-2-phenylindole (DAPI; Thermo Fisher, used with red fluorescent constructs), and then placed on ice under aluminum foil until analysis. Flow cytometry was completed on a DxP FACSCAN analyzer at the Stanford Shared FACS Facility using settings optimized for side scatter (SS), forward scatter (FS), vital dye (PI or DAPI) and fluorophore (BFP, EYFP, GCaMP6, mCherry, sRGECO, or oScarlet) acquisition using positive (non-recombinase-dependent parent construct), negative (empty transfection) and dead (heat-killed; 95°C for 3 min) conditions as controls. Live-cell populations used in comparisons were isolated from debris and dead cells in post hoc analysis using FlowJo 10.4.2 (FlowJo) by (i) positively gating for the high-density population in plotting FS versus SS and (ii) negatively gating for vital dye+ cells. Analysis and plots were completed using FlowJo software.

Analysis of FRT cassette variants was completed by exporting the live-cell populations defined as above, then isolating the population of cells with EYFP expression higher than the maximum expression value of the negative population ('residual population'). Outliers were removed from the negative sample prior to determining the maximum fluorescence value by excluding samples with fluorescence values greater than three median absolute deviations from the median fluorescence. We then calculated the (i) mean fluorescence of the residual population and (ii) the percentage of the total cells represented by the residual population. Flp titration experiments were completed by transfecting a fixed amount of Con/Foff-EYFP variant, Cre, and a varying amount of Flp to create molar ratios as indicated in the figure. A constant amount of DNA was transfected in each condition, with the difference between conditions made up with empty vector.

Primary Neuron Culture Transfection

2 μ g total DNA of mixture of recombinase and INTRASECT construct, or an equivalent amount of the parental tool expression construct, was mixed with 1.875 μ L 2 M CaCl_2 (final Ca^{2+} concentration 250 mM) in 15 μ L H_2O . To DNA- CaCl_2 we added 15 μ L of 2 \times HEPES-buffered saline (pH 7.05). After 20 min at room temperature (20–22°C), the mix was added dropwise into each well (from which the growth medium had been removed and replaced with pre-warmed minimal essential medium (MEM)) and transfection proceeded for 45–60 min at 37°C, after which each well was washed with 3 \times 1 mL warm MEM before the original growth medium was returned. Neurons were allowed to express transfected DNA for 6–8 days prior to experimentation.

Primary Culture Electrophysiology

Recordings of neurons prepared and transfected as above were obtained in Tyrode's medium (in mM: 150 NaCl, 4 KCl, 2 MgCl_2 , 2 CaCl_2 , 10 d-glucose, 10 HEPES, adjusted to pH 7.3–7.4 with NaOH, 320–330 osmolarity) supplemented with Tetrodotoxin (TTX; Tocris, 1 μ M), (2R)-2-amino-5-phosphonopentanoic acid (APV; Tocris, 10 μ M), and 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX; Tocris, 25 μ M) as indicated, with a standard internal solution (in mM: 130 K-gluconate, 10 KCl, 10 HEPES, 10 EGTA, 2 MgCl_2 , to pH 7.25 with KOH, 300–310 osmolarity) in 3- to 6-M Ω glass pipettes. Light from a SPECTRA-X Light Engine (Lumencor) with LEDs with individual light power adjusted for uniform light power density of 1mW/mm² across wavelengths and 470/15, 513/15, and 585/29 filters were used for blue, green and orange illumination, respectively. The Spectra X was coupled with a liquid light guide to an inverted microscope Leica DM-LFSA. All data collected from whole-cell recordings. Recordings were made using a MultiClamp700B amplifier (Molecular Devices). Signals were filtered at 4 kHz and digitized at 10 kHz with a Digidata 1440A analog-digital interface (Molecular Devices). pClamp10.6 software (Molecular Devices) was used to record and analyze data. Peak photocurrents were measured from a 1 or 5 s light pulse in voltage-clamp mode.

Cultured Neuron Calcium Imaging

Calcium imaging conducted on neurons prepared and transfected as above in Tyrode media equivalent to primary culture electrophysiology media, including blockers, except with (mM) 1 MgCl_2 and 3 CaCl_2 . A custom-designed and 3D-printed stimulation insert with platinum wires 1 cm apart was attached to a bipolar stimulator (Warner Instruments) time-locked to imaging software (MetaMorph) via LabVIEW (National Instruments). Stimulation was conducted a 100 mA, 3ms pulse width, 0.1 Hz, with 5 pulses per imaging field and images acquired at 33 Hz. Bulk signal was extracted from manually drawn ROIs and signals were corrected for background fluorescence and GECI signal bleaching prior to calculating dF/F using custom MATLAB code. Baseline F was defined as the median of the first 50 frames (approximately 1.5 s).

Virus production

AAV-8 (Y733F), was produced by the Stanford Neuroscience Gene Vector and Virus Core. In brief, AAV-8 was produced by standard triple transfection of AAV 293 cells (Agilent). At 72 h post transfection, the cells were collected and lysed by a freeze-thaw procedure. Viral particles were then purified by an iodixanol step-gradient ultracentrifugation method. The iodixanol was diluted and the AAV was concentrated using a 100-kDa molecular mass-cutoff ultrafiltration device. Genomic titer was determined by quantitative PCR. All viruses were tested in cultured neurons for expected expression patterns prior to use *in vivo*. Virus titers were obtained for every new batch of virus produced and virus expression was checked in cultured neurons prior to injection *in vivo*. Viral dilutions were calculated based on original titers given at the time of virus production in order to match the viral titer of all viruses used in an experiment. Aliquots of each virus were kept separately from in-use supply and, after all experiments were completed, all viruses used in the Resource were re-titered simultaneously (across two plates) to standardize values across experiments and time and these final re-titered values, and these values are reported in the submitted text, figures, and summary below. As virus titers vary based on probe, standard curve, freeze-thaw cycles, and titer batch, we presented order-of-magnitude rounded titers in the figures and text. Viral titers by figure rounded to nearest order of magnitude are below. Additional details are available in the [Key Resources Table](#).

Figures 3F, 3H, 3I, S6E, and S6F		AAV8-Cre	e10
AAV8-EYFP	e12	AAV8-Flp	e12
AAV8-Con/Fon-EYFP	e12	AAV8-VCre	e13
AAV8-Con/Foff-EYFP	e11		
AAV8-Coff/Fon-EYFP	e12	Figure 5j	
AAV8-Cre	e10, e11, e12	AAV8-3x-G6M	e12
AAV8-Flp	e12	AAV8-Flp	e10
AAV8-Flp-2a-Cre	e12	AAV8-VCre	e11
Figure 4B		Figure S2B	
AAV8-cDIO-EYFP	e12	AAV8-jRGECO1a	e12
AAV8-fDIO-EYFP	e12	AAV8-sRGECO	e12
AAV8-vcDIO-EYFP	e12		
AAV8-Cre	e11	Figure S4F	
AAV8-Flp	e11	AAV8-Arch-EYFP	e12
AAV8-VCre	e12	AAV8-Con/Fon-Arch-EYFP	e12
		AAV8-Con/Foff-Arch-EYFP	e12
Figure 4c		AAV8-Coff/Fon-Arch-EYFP	e12
AAV8-fDIO-EYFP	e12	AAV8-Cre	e12
AAV8-vcDIO-EYFP	e12	AAV8-Flp	e12
AAVretro-Flp	e13	AAV8-Flp-2a-Cre	e12
AAVretro-VCre	e13		
		Figures S6A–S6D	
Figure 5f		AAV8-Con/Foff-EYFP	e11
AAV8-3x-EYFP	e12	AAV8-Flp	e12

Stereotactic injections

Stereotactic viral injections were carried using typical technique. Briefly, mice induced and maintained on isoflurane anesthesia were placed in a stereotactic frame (Kopf Instruments) and the head leveled using bregma and lambda skull landmarks. Craniotomies were performed so as to cause minimal damage to cortical tissue using a hand drill. Injections were made using a 10 μ L syringe and 33 g–36 g beveled needle (World Precision Instruments). 1000 nL of viral suspension was infused at a rate of 100 nL/min at the indicated locations (coordinates in mm below). The needle was left in place for 10 minutes after the completion of injection before being withdrawn under supervision. Skin was approximated with suture.

Stereotactic coordinates (mm) relative to Bregma

	Anterior-Posterior	Medial-Lateral	Dorsal-Ventral
mPFC	+ 1.5	+/- 0.3	- 2.5
mPFC	+ 1.85	+/- 0.3	- 2.5
VTA	- 3.3	+/- 0.4	- 4.2

Slice electrophysiology

To prepare coronal slices (300 μ m) from mice four weeks after viral injection, subjects were first trans-cardially perfused with ice-cold, NMDG-HEPES recovery solution ('NMDG solution'; Ting et al., 2014; in mM): 93 NMDG, 2.5 KCl, 1.2 NaH_2PO_4 , 30 NaHCO_3 , 20 HEPES, 25 glucose, 5 sodium ascorbate, 2 thiourea, 3 sodium pyruvate, 10 MgSO_4 , 0.4 CaCl_2 , adjusted to pH 7.3 – 7.4 with HCl/NaOH. A vibratome with ice-cold, bubbled (5% CO_2 'carbogen') NMDG solution was used to cut slices, which were then recovered for 12 – 14 minutes in carbogen-bubbled NMDG solution at 32°C before being recovered for 1 hr in RT (22– 25°C) carbogen-bubbled artificial cerebrospinal fluid ('aCSF'; in mM): 124 NaCl, 2.5 KCl, 1.2 NaH_2PO_4 , 24 NaHCO_3 , 5 HEPES, 12.5 glucose, 2 MgSO_4 , 2 CaCl_2 , adjusted to pH 7.3–7.4 with NaOH. Synaptic transmission blockers APV (25 μ M), CNQX (10 μ M) and sodium channel blocker TTX (1 μ M) are used as indicated. Electrophysiological recordings were performed at RT. Slices were visualized with an upright microscope LEICA DM LFSA equipped with a 40x water-immersion objective. Individual neuron recordings were obtained after identifying fluorescent protein expression without interruption of ACSF perfusion. Filtered light from a Spectra X Light engine (Lumencor) was coupled to the fluorescence port of the microscope and used to both view fluorescence and deliver light pulses for opsin activation. Whole-cell recordings were obtained with patch pipettes pulled from borosilicate glass capillaries (Sutter Instruments) with a horizontal puller (P-2000, Sutter Instruments) and contained the following internal solution (in mM): 130 K-gluconate, 10 KCl, 10 HEPES, 10 EGTA, 2 MgCl_2 , to pH 7.25 with KOH. Recordings were made using a MultiClamp700B amplifier (Molecular Devices). Signals were filtered at 4 kHz and digitized at 10 kHz with a Digidata 1440A analog-digital interface (Molecular Devices). pClamp10.6 software (Molecular Devices) was used to record and analyze data. Peak photocurrents were measured from a 1 s light pulse in voltage-clamp mode.

Spectrophotometry and Viral Kinetic Analysis

A complete parts list is available in the [Key Resources Table](#). Briefly, data describing viral expression kinetics *in vivo* were collected with an inexpensive device consisting of a 505 nm LED (Thorlabs M505F1) coupled to a dichroic filter mount via multi-mode fiber optic patch cable (Thorlabs m76L01). Excitation light was band-pass filtered (497 nm/16 nm FWHM, Thorlabs MF497-16) and reflected by dichroic (525 nm long-pass, Chroma T525lpxr) into a 200 μ m, 0.53 NA (Doric) fiber optic patch cable to the sample. Emission light then passed through the same dichroic, then through two identical clean-up filters (535 nm/22 nm FWHM, Thorlabs MF535-22), and to a visible wavelength, compact CCD spectrometer (Thorlabs CCS100) via a round-to-linear fiber bundle (Thorlabs BFL200LS02). The spectrometer was connected by USB to a computer running Windows and data acquired with the bundled Thorlabs spectrometer software.

EYFP expression data were acquired from individual animals injected with various AAV8 viruses as indicated (Figure 3) and fitted with 200 μ m, 0.53 NA fiber optic implants (Doric) with the fiber tip placed at the injection site. Animals were injected on Wednesdays (day 0) and the first reading taken on Friday (day 2) with (in ms), 5, 10, 50, 100, 500, 1000, 3000, 5000, 10000, and 20000 integration times, with a large range designed to be sensitive to low expression (longer integration time), but also not saturated with high expression (shorter integration time). Readings were taken every Monday, Wednesday, and Friday thereafter for 6 weeks (18 time points). Animals were sacrificed after time point 18 for expression analysis by confocal. Prior to recording each day, the excitation LED was calibrated to 0.214 mW using a power meter (Thorlabs) and readings from a fluorescein slide (Thorlabs) and purified EYFP were taken to ensure consistent system performance. The raw data were stored as .txt files.

To calculate the 'expression score' of an individual time point, raw data were imported into MATLAB, signal from 528 nm – 540 nm were segmented from the dataset, and the area under the curve was calculated using the *trapz* function across this signal subset for each integration time point. Time points with zero or saturated values were excluded. Remaining values were normalized to integration time and averaged, resulting in that day's expression score.

Virus-dependent expression kinetics were modeled in MATLAB by first log-transforming individual animal expression score datasets, normalizing these log-transformed data to the subject maximum, and pooling the samples within a condition. This combined dataset was then fit with the equation $y = 1/(1 - \exp(-b \cdot x))$ where y is fraction of max expression, x is the days of expression, and b is solved for using the MATLAB *fit* function. Days of expression to a certain fraction of normalized log maximum expression was calculated from fitted curves by solving for x (days of expression) for a given y (fraction of maximum). 95% confidence interval of the fit and the solved days of expression were calculated by using the 95% CI values of b .

To calculate absolute photon number, we calculated a conversion factor between photons and AUC (calculated as above) of a fluorescein slide. To do this, we set the 505 nm excitation LED to 0.214 mW (mJ/s) at the tip of a fiber and connected this fiber to the slide (as above). We next acquired spectrometry data for a series of integration time points between 100 ms and 500 ms, which gave non-zero and non-saturated results. We then disconnected the patch cable (see [Key Resources Table](#)) connecting the optical components to the spectrometer and measured light power coming out of this cable (and thus into the spectrometer) in the absence of ambient light (with the power meter reading 'zero') using a highly sensitive power meter (Thorlabs CS130C) tuned to 534 nm (the median wavelength within our filtered emission range), which was 2.0 nW. We calculated the photon energy (in $J/photon$) using the equation $E = hc/\lambda$, where h is Planck's constant, c is the speed of light, and λ is the photon wavelength, which we set at 534 nm. We next solved for photons/second using E and the measured output emission power in W. Last, we scaled the acquired AUC values to AUC/second and used this set of values to calculate a scale factor x for the spectrometer using the equation $photons/s = x \cdot AUC/s$. To extrapolate this scale factor to absorbance from AUC, we used absorbance values for a single wavelength (534 nm).

Fiber Photometry

Mice were injected in VTA with combinations of 3x-GCaMP6m and recombinase AAV and fitted with 400 μ m, 0.66 NA fiber optic implants (Doric). After four weeks of expression, bulk fluorescence was collected as previously described ([Gunaydin et al., 2014](#)). Calcium signal was collected by recording bulk fluorescence using a single optical fiber while simultaneously delivering excitation light as previously described ([Gunaydin et al., 2014](#); [Inoue et al., 2019](#)). We used a 385 nm LED (M385F1, Thorlabs) for movement correction and 490 nm LED (M490F3, Thorlabs) for calcium signal recording. LEDs were filtered with 386-23 nm (FF01-386/23-25, Semrock) and 488-10 nm (FF01-488/10-25, Semrock) bandpass filters. LED beams were combined using a 425 nm longpass dichroic mirror (T425lpxr, Chroma) before being coupled into an optical fiber patch cable (400 nm diameter, 0.66 NA, Doric Lenses) using a multiband dichroic (ZT405/488/561rpc, Chroma). The far end of the patch cord is end-end coupled to the fiber implant in the animal using 2.5 mm ferrules and zirconia or bronze sleeves. Fluorescent calcium signal emission light was passed through a 555 nm dichroic mirror (FF555-Di03-25x36, Semrock) which was filtered through a 447/522 nm dual band filter (ZET405/488 nm-custom narrow green, Chroma) and then focused onto a femtowatt photoreceiver (Model 2151, Newport) using a lens (62-561, Edmund Optics); note that this system is designed to additionally collect red light and that this feature was not used for these experiments. The signal was sampled at 6.1 kHz and independent signals were recovered using synchronous demodulation techniques, low-pass filtered (corner frequency of 15 Hz, decimated to 382 Hz, then recorded to disk. Calcium signal was calculated for each continuous behavioral recording with custom written MATLAB scripts. First, the 405 nm signal was subtracted from the calcium signal for motion correction. Next, a double exponential was fitted to a thresholded version of the fluorescence time series and the best fit was subtracted from the un-thresholded signal to account for slow bleaching. The fluorescence signal was normalized within each mouse by calculating the dF/F as $(F \text{ median } (F)) / \text{median } (F)$, where the median was taken over the first 100 s of the trial. To shuffle bouts, the bout structure (length of each bout and time between bouts) was preserved, while the starting time of the bouts was randomly placed within the period of the trials when novel objects were present in the arena. When this caused bouts to extend beyond the end of the trial, those bouts were wrapped to the beginning of the object interaction period, again preserving the bout structure. Each trial was shuffled 300 times.

Novel object trials were conducted by placing subjects in a new cage after connecting them to the fiber photometry apparatus by fiber optic patch cable (Doric). Behavior was recorded using an overhead mounted camera and synchronized with fiber photometry using a trial-triggered LED that was mounted below the cage to be out of view of the subject. Animals explored the environment for two minutes before novel objects were introduced. Animals were allowed to continue exploring for five additional minutes before the trial was ended. Videos were scored manually for physical object interactions.

Histology

Mice were trans-cardially perfused with 10 mL of ice-cold 1x PBS followed by 10 mL of 4% paraformaldehyde (PFA). After an overnight post-fix in 4% PFA, brains were equilibrated in sterile 30% sucrose/1x PBS for at least 24 h (or until they sunk in the tube). Tissue was sectioned at 60 μ m using a freezing microtome (Leica) and mounted with DAPI-containing hard-mount solution (H-1500; Vector Laboratories). Images were obtained on a Leica confocal microscope using 5x, 10x, 40x, and 63x objectives. For comparative expression analysis, z stacks with the same settings (z-distance, number of optical slices, acquisition parameters) were taken from the slice judged to have maximum expression. These were analyzed in Image-J (Fiji) by calculating the sum of the total integrated fluorescence extracted from every optical section using a standardized ROI.

QUANTIFICATION AND STATISTICAL ANALYSIS

Statistical analysis was performed with GraphPad Prism 7 and MATLAB. Statistical tests, number of subjects, and significance are as detailed in the figure legends and text. General statistical approaches to analyzing data are as follows:

For two-sample comparisons of a single variable with sample sizes less than 10, we performed an independent, two-sample t test. For simultaneous, pairwise comparisons of multiple, independent variables we performed one-way ANOVA with Sidak's multiple comparison test. For two-sample comparisons with individual sample sizes greater than 10, samples were first analyzed for distribution normality using the Shapiro-Wilk normality test. If any samples from an experiment failed normality testing, comparisons of

unmatched data were performed with a Mann-Whitney test, while matched data comparisons were performed with a Wilcoxon matched-pairs signed rank test; otherwise, an independent, two-sample t test was used.

For multiway comparisons of a single variable with sample sizes less than 10, we performed a one-way ANOVA with follow-up comparison of INTRSECT variants to parental (WT) sample using Dunnett's multiple comparison test. For multiway comparisons with individual sample sizes greater than 10, samples were first analyzed for distribution using the Shapiro-Wilk normality test. If any samples from an experiment failed normality testing, comparisons were performed using a Kruskal-Wallis test with follow-up comparison of INTRSECT variants to parental (WT) sample using Dunn's multiple comparison test; otherwise, a one-way ANOVA was performed.

For comparisons across multiple variables with matched data, we performed two-way ANOVA with follow-up comparison of variants to parental (WT) sample using Dunnett's multiple comparison test.

To examine the linear relationship between related datasets, we first log-transformed data that spanned multiple log scales, then analyzed matched datasets with normal distributions by computing the R^2 value using Pearson correlation. Separately, to test the dependency of a property on an experimental condition, we performed linear regression and examine the R^2 value.

Viral expression kinetic curve fits are described in [Spectrophotometry and Viral Kinetic Analysis](#).

Additional Resources

Deisseroth Lab Website (listing of constructs, sequence maps, and viruses):

http://www.stanford.edu/group/dlab/optogenetics/sequence_info.html

AddGene (repository for most constructs generated in this Resource):

<http://www.addgene.org/> and see [Key Resources Table](#)

Stanford Viral Vector Core (Produced viruses in the Resource and maintains stocks of some of these viruses):

<https://neuroscience.stanford.edu/research/programs/community-labs/neuroscience-gene-vector-and-virus-core>

Flp mouse line database (living document version of [Table 1](#)):

http://www.stanford.edu/group/dlab/optogenetics/flip_lines.html

INTRSECT Standard Operating Procedure (guidelines for experimental design):

https://web.stanford.edu/group/dlab/optogenetics/intrsect_sop.pdf

NetGene2 (Splice site prediction software used for INTRSECT construct design):

<http://www.cbs.dtu.dk/services/NetGene2/>

Neuron, Volume 107

Supplemental Information

Comprehensive Dual- and Triple-Feature


Intersectional Single-Vector Delivery of Diverse

Functional Payloads to Cells of Behaving Mammals


Lief E. Fenno, Charu Ramakrishnan, Yoon Seok Kim, Kathryn E. Evans, Maisie Lo, Sam Vesuna, Masatoshi Inoue, Kathy Y.M. Cheung, Elle Yuen, Nandini Pichamoorthy, Alice S.O. Hong, and Karl Deisseroth

Supplementary Figure 1


A




B




C




D




E




F




G




H




I




J



K




L



Supplemental Figure 1. INTRSECT fluorophore development, related to Figures 1 and 2. A-


C) Optimization of mScarlet. A) We hypothesized that disrupting a lysosomal targeting motif by introducing mutation E95D would reduce aggregation without impairing fluorophore function. B) Cultured neurons expressing mScarlet show obvious aggregates while the mScarlet(E95D) mutant ('oScarlet') do not. C) Summary histogram of aggregates in neurons transfected with mScarlet (red, n=24) or oScarlet (blue, n=19) showing reduced aggregation of oScarlet (mean aggregates oScarlet = 0.579 per neuron, mScarlet = 25.92 per neuron, $p < 0.0001$, Mann-Whitney), while flow cytometry profiling of HEK293 cells transfected with these constructs show equivalent expression (*inset*). Development of INTRSECT oScarlet (D-F), INTRSECT mTagBFP (G-I), and INTRSECT mCherry (J-L). D,G,J) PCR of INTRSECT plasmid DNA does not generate an amplicon while PCR of cDNA from cells co-transfected with same plasmids and activating recombinases results in single expected band (*middle*); the sequences of these cDNA bands are seamless across the exon junction (*bottom-left*). PCR of INTRSECT plasmid DNA generated expected bands with orientation-specific primers (*bottom-right*). E,H,K) Flow cytometry of cells transfected with INTRSECT constructs and indicated recombinases shows high expression for Con/Fon and Con/Foff, while Coff/Fon is modestly lower than WT. Con/Foff shows diminished, but residual, expression when co-transfected with Cre and Flp, while Coff/Fon expression is either indistinguishable from negative control (E) or has a minor, dim residual population (H,K) when co-transfected with Cre and Flp. F,I,L) INTRSECT fluorophores are highly expressed in HEK293 cells when co-transfected with activating recombinases.

Supplementary Figure 2




Supplemental Figure 2. INTRSECT GECI development, related to Figures 1 and 2. A-E) Optimization of jRGECO1a. A) To reduce payload size and decrease observed *in vivo* aggregation, we removed the RSET sequence and disrupted a putative lysosomal targeting motif by introducing mutation E217D to create sRGECO. B) Representative neurons from mouse mPFC four weeks after infection with either jRGECO1a (*left*) or sRGECO (*right*). C) Summary histogram of aggregates per neuron after four weeks of expression *in vivo* (*left*). The distribution of aggregates in sRGECO were significantly less than jRGECO1a (*left*; $p = 0.0368$, Kolmogorov-Smirnov test), while average number of aggregates per neuron in sRGECO (*middle*; 5.732 , $n = 235$) was not significantly less than jRGECO1a (6.958 , $n = 240$; $p = 0.7846$, Mann-Whitney test). Fluorescence expression did not differ between constructs *in vivo* (*right*; $n = 4$ injection sites each, mean total integrated fluorescence sRGECO = 2.47×10^7 A.U., jRGECO1a = 1.86×10^7 A.U., $p = 0.1867$, unpaired t-test). D) To characterize sRGECO function, we constructed a 3D-printed well insert for field stimulation (*left*) that reliably drove signal in cultured neurons expressing Con/Fon-GCaMP6m (*right*). E) sRGECO and jRGECO1a had broadly similar biophysical properties in cultured neurons, albeit with lower basal fluorescence of sRGECO with associated increase in dF/F ($p < 0.01$, unpaired t-tests, n as indicated). Development of INTRSECT sRGECO (F-H), INTRSECT GCaMP6m (I-K), and INTRSECT GCaMP6f (L-N). F,I,L) PCR of INTRSECT plasmid DNA does not generate an amplicon while PCR of cDNA from cells co-transfected with same plasmids and activating recombinases results in single expected band (*middle*); the sequences of these cDNA bands are seamless across the exon junction (*bottom-left*). PCR of sRGECO plasmid DNA generated expected bands with orientation-specific primers (*bottom-right*). G,J,M) Flow cytometry of cells transfected with INTRSECT tools and indicated recombinases show generally high expression comparable to WT, with diminished lower expression in the active configuration of Con/Fon and Coff/Fon. A minor population of cells co-transfected with Cre and Flp are not fully inactivated. H,K,N) INTRSECT tools co-transfected in cultured neurons generate reliable calcium signal in response to field stimulation, with some scattered differences in biophysical properties (*top*; n as indicated, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.005$, **** $p < 0.0005$, Kruskal-Wallis test with Dunn's test). Exemplar $\%dF/F$ traces from culture neuron stimulation show reliable signal from all INTRSECT configurations (*bottom*).

Supplementary Figure 3




Supplemental Figure 3. INTRSECT excitatory opsin development, related to Figures 1 and 2. Development of INTRSECT bReaChES-EYFP (A-C), INTRSECT ChR2(ET/TC)-EYFP (D-F), INTRSECT ChR2(H134R)-mCherry (G-I), and INTRSECT ChRmine3.3-p2a-oScarlet (J-L). A,D,G,J) PCR of INTRSECT plasmid DNA generates an amplicon larger than WT, while PCR of cDNA from cells co-transfected with same plasmids and activating recombinases results in an amplicon equivalent to WT (*middle*). The sequences of these cDNA bands are seamless across the exon junctions (*bottom*). INTRSECT ChR2(H134R)-mCherry was additionally noted to have a smaller PCR product generated by all four cDNA templates and a second, unique product for Coff/Fon. The shared minor amplicon is a truncated sequence splicing exon 1 to exon 3 directly, including in the non-intron-containing WT (noted by *). The tertiary product of Coff/Fon represents a cryptic splice site active only in this logical configuration (*bottom*, noted by #). B,E,H,K) Flow cytometry of cells transfected with INTRSECT tools and indicated recombinases show expression comparable to WT. Diminished, but residual, expression is observed in all constructs for the Con/Foff configuration and in various constructs (B,E) for the Coff/Fon configuration when co-transfected with Cre and Flp. C,F,I,L) Photocurrents of INTRSECT excitatory opsins co-transfected with activating recombinases in cultured neurons are equivalent to WT (*left*; all vs. WT, bReaChES-EYFP $p > 0.5$ for all comparisons, ChR2(ET/TC)-EYFP $p > 0.9$ for all comparisons, ChR2(H134R)-mCherry $p > 0.85$ for all comparisons, ChRmine3.3-p2a-oScarlett $p > 0.2$ for all comparisons, n as indicated, ANOVA with Dunnett's test). Exemplar recordings from whole-cell electrophysiology recordings show reliable excitatory photocurrent from all INTRSECT configurations (*right*).

Supplementary Figure 4




Supplemental Figure 4. INTRSECT inhibitory opsin development, related to Figures 1 and 2. Development of INTRSECT NpHR3.3-p2a-EYFP (A-C), INTRSECT Arch3.3-p2a-EYFP (D-F), and INTRSECT iC⁺⁺-EYFP (G-I). A,D,G) PCR of INTRSECT plasmid DNA generates an amplicon larger than WT, while PCR of cDNA from cells co-transfected with same plasmids and activating recombinases results in an amplicon equivalent to WT (*middle*); a smaller PCR product is noted in all tools for Con/Fon and Con/Foff. The sequences of these cDNA bands are seamless across the exon junctions. The shared minor amplicon (noted by *) is a truncated sequence splicing exon 1 to exon 3 directly; high-quality sequencing of minor products for NpHR3.3-p2a-EYFP (A) was only obtained for Con/Fon and Con/Foff PCR products. B,E,H) Flow cytometry of cells transfected with INTRSECT tools and indicated recombinases show expression comparable to WT. Diminished, but residual, expression is observed in all constructs for the Con/Foff configuration and in some constructs (E,H) for the Coff/Fon configuration when co-transfected with Cre and Flp. C,F,I) Maximum photocurrents and hyperpolarizations of INTRSECT tools co-transfected with activating recombinases in cultured neurons are equivalent to WT for NpHR3.3-p2a-EYFP and iC⁺⁺-EYFP (*left*; all vs. WT, NpHR3.3-p2a-EYFP $p > 0.9$ for all comparisons, iC⁺⁺-EYFP $p > 0.05$ for all comparisons, n as indicated, ANOVA with Dunnett's test, measurements of the chloride channel iC⁺⁺ taken at -40mV (Berndt et al., 2016)). INTRSECT Arch3.3-p2a-EYFP showed reduced photocurrents for Con/Fon and Con/Foff (all vs. WT, Con/Fon $p = 0.0143$, Con/Foff $p = 0.0123$, Coff/Fon $p = 0.4551$, n as indicated, ANOVA with Dunnett's test) and reduced hyperpolarization for Con/Foff (all vs. WT, Con/Fon $p = 0.2730$, Con/Foff $p = 0.0264$, Coff/Fon $p = 0.1252$, n as indicated, ANOVA with Dunnett's test). Acute mPFC slice recordings from neurons expressing WT and INTRSECT Arch3.3-p2a-EYFP four weeks post-infection showed equivalent photocurrents for these two logical configurations and significantly increased photocurrent for Coff/Fon (*F-top left*; all vs. WT, n as indicated, Con/Fon $p = 0.3966$, Con/Foff $p = 0.9286$, Coff/Fon $p = 0.0001$, ANOVA with Dunnett's test), while hyperpolarization in slice are equivalent to WT (*F-bottom left*; all vs. WT, $p > 0.75$ for all comparisons, n as indicated, ANOVA with Dunnett's test). Exemplar recordings from whole-cell electrophysiology recordings show reliable inhibitory photocurrent from all INTRSECT configurations (C,F,I - *right*).


A




B




C




D




E




F




G



H



I




Supplemental Figure 5. Optimization of the Con/Foff INTRSECT backbone, related to Figure 3. A) Con/Foff-EYFP variants with modified sequences noted by triangles (recombinase recognition sequences) and bars (additional 14bp sequences). Triangle direction notes orientation of central recognition site motif relative to promoter. The original INTRSECT 'F3/F5' cassette is noted throughout by 'v1'. B) Variants were screened by flow cytometry and the residual population was defined as having fluorescence intensity greater than the maximum intensity of the negative control. Mean EYFP signal of this residual population and percentage of total population remaining positive, were used as the read-outs of variant function. C) Variants were refined sequentially through three rounds of screening. FRT/F5 ('g') and 14bp-FRT/F5 ('o') were consistently superior to v1 with significantly decreased mean signal and percentage of total population ($n = 5$ separate experiments, all vs. v1, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0005$; ANOVA with Dunnett's test). Dashed blue boxes indicate variants further modified in subsequent screening round. There was no difference in high expression levels of variants 'g' or 'o' in the active configuration. D,E) Two Con/Foff-EYFP variants ('g', 'o') decrease residual expression mean EYFP fluorescence (D) and the fraction of residual cells (E) compared to Con/Foff(F3/F5)-EYFP ('v1') over a broad range of Flp:Cre ratios in co-transfected HEK293 cells (compared to v1, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$, $n = 5$ independent experiments, ANOVA with Dunnett's test), although further increasing the ratio beyond 10:1 showed marginal further increase toward the fitted plateau values (R^2 mean expression v1 = 0.8028, g = 0.7114, o = 0.6921; R^2 fraction of residual cells v1 = 0.2793 g = 0.5848, o = 0.3983). There was no significant difference in the magnitude of improvement for either residual fluorescence (D-bottom) or fraction of residual EYFP+ cells (E-bottom) between the two improved variants ($p > 0.25$ for all comparisons, ANOVA with Sidak's test). F) Decreased residual expression was maintained *in vivo* for both variants 'g' and 'o' relative to 'v1' in animals co-injected with viral Con/Foff variants and Cre-2a-Flp (data normalized to AAV-Cre controls, residual fluorescence relative to v1: g = 0.4066, $p = 0.0009$, $n = 3$ animals, o = 0.4003, $p = 0.0008$, $n = 3$ animals, ANOVA with Dunnett's test). The FRT/F5 variant ('g') was chosen for the Con/Foff INTRSECT backbone to facilitate cloning. G-I) Comparison of mean signal (*left*) and percentage of total population (*right*) of all 15 INTRSECT Con/Foff tools in the FRT/F5 configuration relative to original (F3/F5) versions in HEK293 cells co-transfected with Cre alone (G; active configuration; mean relative signal of FRT/F5 = 1.046, $p = 0.4578$, relative percentage of total population = 1.038, $p = 0.4733$), co-transfected with Cre AND Flp (H; inactivated configuration, relative mean signal = 0.807, $p = 0.0069$, relative percentage of total population = 0.8214, $p = 0.0101$, $n = 15$ individual constructs, all comparisons paired t-tests). I) Data from (H) normalized to Cre alone controls (normalized relative mean signal = 0.8445, $p = 0.0795$, normalized relative percentage of total population = 0.7894, $p = 0.0010$, paired t-tests).

Supplementary Figure 6



A

SST::Cre transgenic

AAV-Con/Foff(FRT/F5)-EYFP




AAV-Con/Foff(FRT/F5)-EYFP + Flp



B


Hippocampus




C

SST::Cre transgenic

AAV-Con/Foff(FRT/F5)-EYFP




AAV-Con/Foff(FRT/F5)-EYFP + Flp




D

mPFC




E

Con/Foff(FRT/F5)-EYFP + Cre (e12)



- Con/Foff(FRT/F5)-EYFP e12 + Cre
- Con/Foff(FRT/F5)-EYFP e11 + Cre
- Con/Foff(FRT/F5)-EYFP e10 + Cre

F



- EYFP
- Con/Fon + Flp-2a-Cre
- Fon/Coff + Flp
- Con/Foff(FRT/F5) + Cre e12
- Con/Foff(FRT/F5) + Cre e11
- Con/Foff(FRT/F5) + Cre e10

Supplemental Figure 6. Con/Foff(FRT/F5) is highly efficient *in vivo*, related to Figure 3. A-D) AAV-Con/Foff(FRT/F5)-EYFP is highly expressed in a Cre transgenic mouse and is inactivated by AAV-Flp. A,C) Injection of AAV-Con/Foff(FRT/F5)-EYFP in the hippocampus (A) or mPFC (C) of a SST-Cre transgenic mouse shows expected high expression when injected alone (*left*) which is inactivated when co-injected with AAV-Flp (*right*). DAPI for comparison. B,D) SST-Cre animals show a consistently high level of expression when injected with AAV-Con/Foff(FRT/F5)-EYFP alone in the hippocampus (B; vs. AAV-Flp $p = 0.0003$; vs WT $p = 0.0007$; ANOVA with Tukey's test) or mPFC (D; vs. AAV-Flp $p = 0.0014$; vs WT $p = 0.0027$, ANOVA with Tukey's test), while expression in animals co-injected with AAV-Flp is indistinguishable from wild-type animals (hippocampus $p = 0.1481$, mPFC $p = 0.7208$, ANOVA with Tukey's test). E) Observed *in vivo* viral toxicity observed with high titers of AAV-Cre (Figure 3H) is independent of AAV-Con/Foff(FRT/F5)-EYFP titer. F) Comparison of the measured *in vivo* viral expression score immediately prior to animal sacrifice and post-hoc total integrated fluorescence measured by confocal are positively correlated ($R^2 = 0.5123$, $p < 0.0001$, $n = 30$, Pearson correlation of log-transformed data).

Supplementary Table 1

Oligo Name	Sequence (5' -> 3')
Sequencing nEF F	GACCCTGCTTGCTCAACTCT
Sequencing EF1a F	TGGAATTTGCCCTTTTGGAG
Sequencing Intron 1 F	GGGACGACATGACTTAACCAG
Sequencing Intron 1 R	CCAGCCCTTCTCATGTTCAAG
Sequencing Intron 2 F (only 2-intron constructs)	CCTGTATGTGACCCATGTGC
Sequencing Intron 2 R (only 2-intron constructs)	GCACATGGGTACATACAGG
Sequencing WPRE R	GGGCCACAACCTCATAAA
Arch-EYFP RT F	CTTCTACTTTCTGGTCCGCG
Arch-EYFP RT R	AAGTCGTGCTGCTTCATGTG
BFP RT F	ACCGTGGACAACCATCACTT
BFP RT R	ATGTCGTTTCTGCCTTCCAG
bREACHes-EYFP RT F	GACCAGCTACACCCTGGAGA
bREACHes-EYFP RT R	AAGTCGTGCTGCTTCATGTG
ChR2-EYFP RT F	CAATGTTACTGTGCCGGATG
ChR2-EYFP RT R	AAGTCGTGCTGCTTCATGTG
ChR2-mCherry RT F	CAATGTTACTGTGCCGGATG
ChR2-mCherry RT R	CTTGTACAGCTCGTCCATGC
GCaMP6M RT F	ACTTCAAGATCCGCCACAAC
GCaMP6M RT R	TCCCCGTCCTTGTCAAATAG
GCaMP6F RT F	ACTTCAAGATCCGCCACAAC
GCaMP6F RT R	TCCCCGTCCTTGTCAAATAG
iC++-EYFP RT F	AACAAGCGTACCATGGGTCT
iC++-EYFP RT R	AAGTCGTGCTGCTTCATGTG
mCherry RT F	CCTGTCCCCTCAGTTCATGT
mCherry RT R	CTTCAGCTTCAGCCTCTGCT
NpHR-EYFP RT F	GTTGTTTCGAGTTCGTGCTGA
NpHR-EYFP RT R	AAGTCGTGCTGCTTCATGTG
oScarlet RT F	CCATGAACGGCCACGAGTTCG
oScarlet RT R	GTCCAACCTGCGGTCCACGTTG
srGECO RT F	CAACGAGGACTACACCATCG
srGECO RT R	GTCCTCGAAGTTCATCACGC
3xEYFP RT F	AGCTGGACGGCGACGTAAA
3xEYFP RT R	GCTCGTCCATGCCGAGAGTG
3xGCaMP6M RT F	GATCACATGGTCCTGCTGGA
3xGCaMP6M RT R	ATCCCCATCGATGTCTGCTT

Supplementary Table 1. cDNA sequencing and reverse transcription DNA oligos, related to Figures 2,5,s1-s4. DNA oligos used for routine plasmid sequencing and quality control (Oligo Names starting with 'Sequencing') and oligos used for RT-PCR and PCR product sequencing (Oligo Names containing 'RT'). 'F' denotes forward (sense) primer, 'R' denotes reverse (anti-sense) primer. 'Sequencing' primers designed to bind to promoter sequence ('nEF' and 'EF1a'), within the conserved intron regions ('intron X'), or WPRE element. RT-PCR primers sit within ORF of noted plasmids; for two-intron constructs (e.g. Chr2-EYFP), F primer binds within exon 1 while R primer binds within exon 3, with both splice sites in between. Sequences given 5' to 3'. All oligos synthesized by IDT.